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Background: Escherichia coli (E.coli) O86a:K61 belongs to the Enteropathogenic E. coli (EPEC) group of 
pathogens.  Acute gastroenteritis affects 2-4 billion people annually and EPEC is associated with 10-40% 
of hospitalized diarrhea cases globally. Coagulation Factor (F) V circulates as an inactive procofactor (Mr 
330kDa) which upon thrombin activation to the active cofactor, FVa, functions in prothombinase to 
accelerate prothrombin to thrombin conversion by 300,000-fold. The ability of E.coli O86a:K61 to cause 
intestinal hemorrhage is of interest because previous research demonstrated that during E.coli 
O86a:K61 sepsis in baboons, a dose-dependent inactivation of FV was observed as the bacterial dose 
increased. These results suggested a secreted E.coli protease may have mediated this effect on FV. This 
research has focused on the purification, identification, and characterization of a secreted E. coli 
O86a:K61 protease that inactivates FV. The final partially-purified protease inactivated FV to a 250kDa 
product by immunoblotting, and possessed a 900-fold increase in specific activity versus FV in human 
plasma compared to the culture supernatant. At least 3 proteins were observed upon SDS-PAGE. 
Proteolytic inactivation of FV was activated by up to 500-fold with β-mercaptoethanol and 2-fold with 
1M urea. The protease was heat stable retaining all of its activity versus FV after 1h at 70°C or 80°C, and 
partial activity (50%) at 95°C. Proteolysis of FV was blocked by 90% with alpha-1-protease inhibitor; 
however, the protease was resistant to 1.5 mM PMSF, and unaffected by E64, or iodoacetamide. FV is a 
major regulator of the coagulation process and its inactivation by the secreted E.coli protease would be 
expected to result in a net bleeding tendency which may contribute to the mucosal hemorrhage 
observed in humans with associated hemorrhagic colitis. Proteolytic inactivation of FV is predicted to 
result in decreased bacterial containment by host fibrin thereby increasing pathogen survival and 
growth. FV inactivation by the secreted E.coli protease may be part of a novel pathogenic virulence 
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The Coagulation System 
The primary function of the coagulation system is to prevent blood loss in response to injury or 
trauma.  The coagulation system is characterized by a number of unusually large zymogens and 
procofactors that require serine protease activation for sequential, rapid, highly localized production of 
an insoluble fibrin clot. The coagulation cascade may be initiated by one of two pathways: the contact 
(Intrinsic) pathway, or the tissue factor (Extrinsic) pathway.  Activation of either pathway results in the 
activation of the Common pathway, and the generation of thrombin, the master serine protease 
regulator of the coagulation cascade, and the enzyme that converts soluble fibrinogen into an insoluble 
fibrin clot. 
Activation of the contact pathway occurs after damage to endothelium lining of the blood 
vessel.  Factor (F)XII is activated after coming into contact with the electronegative surface of damaged 
endothelial and sub-endothelial cells. The active serine protease, FXIIa, then activates FXI and 
prekallikrein, to FXIa and kallikrein, respectively.  These proteins are anchored to the vessel wall by high 
molecular weight kininogen (HMWK). Kallikrein serves to further activate neighbouring FXII proteins in a 
positive feedback loop, whereas FXIa, when in complex with its thrombin activated cofactor VIIIa 
(Intrinsic tenase), proteolytically activates FX into FXa.  Activation of FX marks the end of the Contact 
activation pathway, and the beginning of the Common pathway.  
The tissue factor pathway is considered the most essential pathway for the production of a 
fibrin clot. This notion is based on the observation that individuals deficient in contact factors, FXII, FXI, 
kininogen, or kallikrein do not suffer from bleeding disorders (Colman and Schmaier 1997). As its name 
implies, activation of the Extrinsic pathway requires activation by tissue factor (TF), a protein which is 
sequestered away from the bloodstream in the non-injured/ normal state. Upon vessel  
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Figure 1 The Blood Coagulation Cascade. The coagulation cascade is divided into an Intrinsic, Extrinsic, 
and a Common pathway. Coagulation factors of the Entrinsic pathway are represented in black, 
coagulation factors of the Extrinsic pathway are represented in purple, coagulation factors of the 
Common pathway are represented in green, and are designated by an “a” upon activation. Arrows 
symbolize the proteolytic conversion within the respective pathway. Factors in red are inhibitors and red 
arrows symbolize inactivation events. Proteins that participate in the fibrinolysis system are represented 
in orange. The following abbreviations are used: F, factor; HK, high molecular weight kininogen; PK, 
plasma kallikrein; TFPI, tissue factor pathway inhibitor; tPA, tissue plasminogen activator; and uPA, 









damage, TF is exposed to the bloodstream on the cell membrane of subendothelial cells, platelets, and 
leukocytes.  When TF is exposed to the blood, it complexes and activates the serine protease FVII to 
FVIIa.  The TF-FVIIa complex is then capable of activating FIX (Contact pathway) and FX, initiating the 
Common pathway. 
The Common pathway begins with the generation of the active serine protease FXa. Initially FXa 
alone is capable of converting small amounts of prothrombin (FII) to thrombin (FIIa). Thrombin is then 
capable of activating the procofactor FV to FVa, allowing it to complex with FXa, calcium, and an anionic 
membrane (Prothrombinase complex), effectively increasing the rate of conversion of prothrombin to 
thrombin by approximately 300,000-fold (Krishnaswamy et al 1987). Sufficient activation of prothrombin 
to thrombin inevitably results in the generation of a fibrin clot.  Thrombin is also capable of activating 
several proteins upstream in the cascade, resulting in a positive feedback loop.  Thrombin proteolytically 
activates FXI, FIX, FVIII, and FV, resulting in the generation of additional thrombin.  Thrombin also 
proteolytically activates fibrinogen (FI) to its insoluble and self polymerizing form, fibrin (FIa). The 
transglutaminase FXIII is also activated by thrombin to FXIIIa.  FXIIIa crosslinks and stabilizes the 
developing fibrin clot, and prevents the clot’s proteolytic degradation. 
Regulation of the Coagulation Cascade 
Activation of the coagulation cascade must be rapid, and highly localized to prevent blood loss; 
however, the system must be tightly regulated to prevent unwanted fibrin deposition.  The coagulation 
system is regulated at several levels of the cascade.  Thrombin, the master regulator of the cascade, is 
essential to the production of fibrin; however, it also functions in preventing excessive clot formation by 
binding to thrombomodulin (TM), a membrane bound protein of the endothelium. When thrombin is 
bound to TM, it is converted from a procoagulant enzyme to an anticoagulant enzyme.  The 
thrombin/TM complex is not capable of activating fibrinogen, but instead rapidly activates the 
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anticoagulant protease protein C to activated protein C (APC). APC, in combination with its cofactor 
Protein S, inhibits further generation of thrombin by proteolytically inactivating FVa and FVIIIa, which 
are the essential cofactors for the Prothrombinase and Intrinsic tenase complexes, respectively. The 
circulating protease tissue factor pathway inhibitor (TFPI) ensures that the developing fibrin clot does 
not spread to unwanted areas of the circulatory system by inhibiting the TF/VIIa complex, and FXa (Jesty 
et al 1996). Antithrombin (AT) is also a potent inhibitor of fibrin formation by inhibiting thrombin 
directly in a 1:1 ratio, a process which is catalyzed by heparin (Rosenberg and Damus, 1973). AT also 
inactivates FXa, FIXa, FXIa, and to some extent the TF/FVIIa complex (Carlson et al 1985). These 
inhibitors of coagulation are necessary to allow for normal hemostasis.  
After vessel injury and subsequent fibrin formation, the fibrin clot must be broken down as 
tissues are repaired and the wound is healed.  It is the role of the fibrinolysis system to degrade fibrin 
when it is no longer needed.  Plasminogen is a circulating zymogen which is activated by tissue 
plasminogen activator (tPA) or by urokinase-type plasminogen activator (uPA) to plasmin, directly on the 
fibrin surface.  The serine protease plasmin is responsible for the degradation and solubilisation of the 
fibrin clot to fibrinogen degradation products (FDPs). The coagulation system and the fibrinolytic system 
are tightly regulated to maintain hemostasis. Over-activation of the coagulation system or under-
activation of the fibrinolytic system results in thrombosis (Excessive clot formation), whereas under-
activation of the coagulation system or over-activation of the fibrinolytic system results in bleeding 
tendencies. 
Factor V  
Factor V (FV) is a key regulator of thrombin generation, and thus the overall coagulation 
process.  Individuals who are deficient of functional FV (Parahemophilia) present with bleeding 
tendencies in the skin (44%), mucosa (44%), joints (23%), muscles (23%), genitourinary tract (19%),  
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Figure 2 Factor V Activation and Participation in the Prothrombinase Complex. A diagram of the 
organization of the human factor V molecule with domain structure is depicted in Panel A. Activation of 
FV by thrombin to the active procofactor, FVa, is the result of 3 sequential cleavages in the B-domain, 
which then dissociates. Following activation, the active cofactor is a heterodimer composed of a heavy 
chain, a divalent cation and an associated light chain. Once activated by thrombin, FVa is capable of 
participating in the Prothrombinase complex (Panel B). FVa in combination with a phospholipid 
membrane, calcium, and the serine protease FXa, can then proteolytically activate prothrombin to 
































gastrointestinal tract (6%), and the central nervous system (8%) (Huang and Koerper 2008). FV was 
discovered by Owren in 1943 (Owren and Cooper 1955), and first purified to homogeneity in 1979 by 
Nesheim (Nesheim et al 1979).  FV circulates in human plasma at approximately 20-40nm as a 
330,000kDa procofactor, with a domain structure of A1 A2 B A3 C1 C2. In addition, approximately 20% 
of the total human FV pool is present in platelet α-granules. The 2196 amino acid procofactor is 
synthesized primarily in the liver; however, megakaryoctes are also capable of synthesizing FV. FV is 
activated in vivo by 3 sequential cleavages in the B-domain by thrombin at Arg709, Arg1018, and Arg1545 
(Orfeo et al 2004).  The B domain then dissociates from the active FVa molecule, which can then bind 
FXa on a phospholipid membrane surface to form the Prothrombinase complex.  This complex is the 
essential activator of prothrombin, as it increases the conversion of prothrombin to thrombin by 
300,000-fold, compared to FXa acting alone.  APC is the primary physiological regulator of FVa.  Protein 
C is activated by thrombin, when coupled with the cofactor TM as part of a negative feedback loop.  APC 
inactivates FVa by competing for binding with FXa; once in complex with FVa, APC proteolytically cleaves 
FVa at residues Arg506, Arg306, and Arg679 of the heavy chain. Individuals with the FVLEIDEN allele generate a 
FVa molecule which is resistant to inactivation by APC. FVLEIDEN represents the most common genetic 
cause of venous thrombosis in humans (Dahlback 2003); therefore, FV activation and inactivation are 
essential to maintaining normal hemostasis.  
The Coagulation System and the Innate Immune Response 
The coagulation systems and the immune system are interconnected and the most striking 
evidence of the interplay between the two systems comes from the horseshoe crab which has a 
completely integrated system that evolved nearly 500 million years ago and remains unchanged today 
(Delvaeye and Conway 2009). The coagulation system provides the host with a means to quarantine and 
sequester the infectious agent.  The coagulation system is activated in general proximity to, or directly 
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on the bacterial cell membrane (Loof et al 2011) effectively preventing pathogen dissemination 
throughout the host and allowing for a localized immune response.  The generation of Prothrombinase, 
and subsequently thrombin, is essential to preventing bacterial infection. 
  Thrombin generation in response to bacterial infection induces the release of proinflammatory 
cytokines from endothelial cells, mural cells, epithelial cells, adipocytes, and immune cells (Drake et al 
1992; Fujita et al 2008; Wadgonkar et al 2008).  Thrombin acts as a chemotactic factor for monocytes 
and neutrophils, and it is capable of directly activating complement component 5 (Huber-Lang et al 
2006). Degradation of fibrin also stimulates the inflammatory response through activation of cytokines 
and chemokines such as TNF-α, IL-β, and macrophage chemotactic protein-1 (Szaba and Smiley, 2002).  
These inflammatory cytokines and chemokines also activate the coagulation system.  Without proper 
regulation the inflammatory response enhances the coagulation process; that in turn, enhances the 
inflammation response, this process may cycle out of control and result in severe pathological 
conditions such as disseminated intravascular coagulation (DIC), which is associated with extremely high 
mortality rates (Esmon, 2005).  
Bacteria and the Coagulation System 
It is not surprising that bacteria have evolved mechanisms to subvert the coagulation system 
during infection.  The coagulation system, like the immune system, may be deregulated by an invading 
bacterium to enhance their growth and survival.  Several virulence factors have been identified which 
are capable of either activating or inactivating the coagulation system depending on which is more 
advantageous to the pathogen.  It is theorized that during early stages of infection it may be 
advantageous to the pathogen and the host to initiate coagulation. This allows for the generation of a 
fibrin “shield” around the pathogen, which provides protection against phagocytosis by 
monocytes/macrophages, and allows for proliferation while preventing dissemination throughout the 
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host.  However, once critical numbers are reached the bacteria may degrade the surrounding fibrin clot 
and disseminate throughout the host, and to new hosts. Others theorize that the activation of the 
coagulation system allows for the generation of a fibrin clot at the site of infection providing a localized 
immune response and containment for the host, and that bacterium have evolved means to prevent this 
from occurring.  Either of these views requires the eventual breakdown of the clot to allow for 
dissemination of the pathogen.  Both Escherichia coli (E. coli) and Salmonella spp express cell surface 
organelles which are capable of binding and depleting coagulation factors, which promote a 
hypocoagulatory state in mice (Herwald et al 1998). 
Secreted Bacterial Proteases and the Coagulation System 
Bacterial extracellular proteases from different pathogens provide resistance against the host 
immune defence system. Proteases from a variety of pathogens are essential virulence factors during 
infection.  They may act to degrade antibodies (Molla et al 1988), complement proteins (Oda et al 1990), 
and may increase vascular permeability (Kaminishi et al 1990). Bacterial proteases may also deregulate 
the coagulation system, or directly degrade fibrin (Imamura et al 1995). There are two ways this may be 
accomplished: activation of host proteins which normally regulate coagulation or direct inactivation of 
coagulation proteins.  Plasminogen activator (Pla), a membrane bound protease of Yersinia pestis which 
is essential to pathogenicity (Suomalainen et al 2007) activates the human zymogen plasminogen to its 
active and potent anti-coagulant form, plasmin. The protease is also capable of inactivating the main 
circulating inhibitor of plasmin α-2-antiplasmin. Arginine gingipain A (RgpA), Arginine gingipain B (RgpB), 
and Lysine gingipain (Kgp) are secreted/vesicle-bound cysteine proteases of Porphyromonas gingivalis 
which are capable of directly degrading fibrinogen in human plasma (Imamura et al 1995). EspP 
(Extracellular serine protease plasmid-encoded) is a secreted protease of E. coli O157: H7 that is capable 
of directly cleaving human coagulation FV (Brunder et al 1997).  
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Outer Membrane Vesicles 
Secreted proteins of several pathogenic bacteria are critical to establishing colonization and 
virulence within their hosts. In addition to secreted virulence mechanisms, outer membrane vesicles 
(OMVs) of gram-negative bacteria may be implemented to establish a colonization niche. OMVs are 
produced via blebbing of gram-negative bacterial outer membranes and have been frequently regarded 
as cell debris or microscopy artefacts (Kulp and Kuehn 2010). No inner membrane or cytosolic 
components are incorporated into OMVs, suggesting that the blebbing of the outer membrane occurs in 
an organized fashion; however, little is known about the mechanism of OMV formation (Haurat et al 
2010). OMVs are produced ubiquitously under the appropriate growth conditions from both pathogenic 
and non-pathogenic bacteria. OMVs may be used to facilitate horizontal gene transfer as they readily 
take up exogenous DNA; they are used in cell defence during phage infection, and to concentrate 
enzyme/enzyme complexes in their environment without expending energy in moving the cell.  OMVs 
provide a protective function, allowing for transport of otherwise labile components (Such as protease-
susceptible peptides) through the environment (Kesty and Kuehn 2004). OMVs from pathogenic bacteria 
are rich in lipopolysaccharide (LPS) and are associated with a variety of virulence factors such as: 
proteases, adhesins, hemolysins, toxins (Bomberger et al 2009; Haurat et al 2010) and have the ability to 
absorb host antibodies (Kulp and Kuehn 2010).  These so-called “bacterial bombs” attack host tissues, 
deregulate host defences, and are involved in the hijacking of host cell processes (Mashburn-Warren 
and Whitely, 2006) which has resulted in intensive research over the past 5-10 years. Several pathogenic 
E. coli have been shown to secrete OMVs containing toxins such as heat-labile enterotoxin (Kuehn and 
Kesty 2005), Shiga toxin, and Cytolysin A (Yokoyama et al 2000). Injection of only 25µg of OMVs from 
intestinally derived E. coli resulted in systemic inflammatory response syndrome and death after 36h in 
mice (Park et al 2010). However, no OMV proteases have been reported to interact with the coagulation 
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system. Proteases have not been reported to associate with E. coli OMVs, nor have OMVs been reported 
with Enteropathogenic E. coli (EPEC) strains such as E. coli O86a: K61.   
Bacteria and Factor V 
The procofactor FV is essential to maintaining normal hemostasis. This is most clearly 
demonstrated in mice where FV deficiency is associated with a completely lethal phenotype during early 
embryonic development (Cui et al 1996). Curiously, only 0.1% of normal FV levels are required to rescue 
the lethal phenotype in mice (Mann 2000).  Platelet or plasma derived FV levels have a direct effect on 
survival in Streptococci-induced sepsis models in transgenic mice (Sun et al 2009). In Sun et al (2009); 
transgenic mice were generated which had 45% or 15% plasma derived FV with no platelet pool, or 3% 
normal platelet FV levels with no plasma derived FV.  Interestingly, significant differences in mortality 
rates were observed in each group, and compared to controls which had normal FV levels after 
experimentally induced sepsis with Streptococcus pyogenes. Sun et al (2009) clearly demonstrated the 
importance of FV during bacterial infection, and their results possibly explain the necessity of generating 
1000-fold more FV than is necessary to maintain the coagulation health of the host.  FV inactivation 
during bacterial infection would therefore be expected to increase morbidity/mortality in infected 
patients, by promoting a net bleeding tendency.  During experimental E. coli O86a:K61 induced sepsis in 
baboons, a dose dependant relationship of FV inactivation was observed with increasing doses of 
infused bacteria (Samis et al 2009). Infusion of baboons with 2.40 x 106 (Low), 1.05 x 108 (Medium), or 
6.49 x 108 (Lethal) cfu kg-1 of E. coli O86a:K61 resulted in the reduction of FV activity to 80%, 50%, or 20% 
of pre-infusion levels, respectively. Also, inactivation of FV was associated with the generation of a 
250kDa cleavage product. These results suggest that a secreted E. coli protease may have mediated the 
cleavage and inactivation of baboon FV. FV inactivation may be essential to the establishment of E. coli 
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infection, as several strains are capable of producing proteases which degrade FV directly; or indirectly 
via activation of host proteases. 
The high prevalence of the FVLEIDEN allele (4.4% of Caucasians in America) (Gregg et al 1998) 
which encodes a FV protein that is resistant to inactivation by the host protease APC, and is associated 
with thrombosis in carriers, also speaks to the importance of FV activity during infection.  One would 
expect heavy selective pressure to remove the FVLEIDEN allele from the human population; however, 
FVLEIDEN is thought to infer resistance to infection, and this has been demonstrated in LPS challenged 
mice (Weiler et al 2004).  It is not surprising that FV is a target of several virulence factors during 
infection: EspP, EspC (Enteropathogenic E. coli protease C), Pet (Plasmid-encoded toxin), Pic (Protease 
involved in intestinal colonization), and Sat (Secreted autotransporter toxin), which belong to the family 
of SPATEs (Serine protease autotransporters of Enterobacteriaceae) and are all capable of cleaving FV. 
These proteases are capable of directly cleaving FV in human plasma, or FV that is added to serum, 
however, the effects on FV functional coagulation activity were not investigated (Brunder et al 1997). 
Aside from the SPATEs, several E. coli strains also produce OmpT (Outer membrane protein T), a 
membrane bound protease which is capable of activating the host fibrinolytic protease plasminogen to 
plasmin (Sodeinde and Goquen 1989).  The primary role of plasmin is to degrade fibrin; however, it also 
proteolytically inactivates FVa and FVIIIa. Therefore, FV is an important protein during bacterial 
pathogenesis and a virulence target during E. coli infections. 
Study Rationale 
E. coli is responsible rational for numerous human and animal diseases including: diarrhea, 
hemorrhagic colitis, haemolytic-uremic syndrome, urinary tract infection, systemic inflammatory 
response syndrome, and sepsis (Johnson et al 2005; Johnson and Russo 2001; Chen and Frankel 2005; 
Laupland et al 2008; Croxen and Finlay 2010; Park et al 2010). It has been estimated that E. coli related 
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infections cost the US healthcare system approximately 1.1-2.8 billion dollars annually and accounted 
for approximately 40,000 deaths in 2001 alone (Russo and Johnson 2003). Traditionally, E. coli infections 
have not commanded attention due to the susceptibility of E. coli to antimicrobial therapy; however, 
antibiotic resistance amongst E. coli clinical isolates has been steadily increasing (Gupta et al 2001). Due 
to the emergence and increasing prevalence of antimicrobial resistance, new therapeutic approaches 
are required. Targeting virulence factors as an alternative approach to antimicrobial therapy is 
promising because it may allow clinicians to prevent pathogenesis without putting heavy selective 
pressures on the pathogen to evolve resistance (Cegelski et al 2008). Since it has been previously 
demonstrated that FV is not only a critical component of the host’s coagulation system, but also of the 
immune response during bacterial infection, the goal of this study was to characterize and identify a 
secreted E. coli protease which is capable of cleaving and inactivating human FV in human plasma.   
Hypothesis  
Factor V is inactivated by an unknown secreted protease from E. coli O86a:K61 as part of a novel 
virulence mechanism that deregulates the coagulation process. Proteolytic cleavage and inactivation of 
FV would be expected to cause a net bleeding tendency in E. coli infected hosts. 
Study Objectives 
i) Develop a FV activity assay to complement immunoblotting techniques in order to 
demonstrate that inactivation of FV is associated with proteolytic cleavage by an E. coli 
protease. 
ii) Purify, identify, and characterize the protease from the culture supernatant of E. coli 
O86a:K61 which is capable of cleaving and inactivating human FV in plasma. 
iii) Assess the clinical relevance of FV inactivation in patients suffering from sepsis-induced DIC. 
iv) Assess the prevalence of E. coli strains which are capable of inactivating FV. 
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v) Elucidate the role(s) of proteases as part of a common virulence mechanism used by 




Materials and Methods 
Protein Quantification 
Protein concentration was measured by absorbance at 280nm, the Bradford method, or the 
bicinchoninic acid (BCA) protein assay. 
Absorbance at 280nm 
Samples of interest were added to a 96-well UV compatible plate (Costar, Mississauga, ON), to a 
final volume of 200µl with or without dilution.  The samples were blanked against 200µl of the same 
buffer. Absorbance was measured at 280nm in a microplate-reader (Molecular Devices, Sunnyvale, CA) 
and the sample absorbance measurement was corrected with buffer blanks.  Protein concentration was 
determined using a path length of 0.58cm and an extinction coefficient of 1mg/ml/cm with the Beer–
Lambert law equation. All samples were diluted in buffer to give an absorption measurement less than 
1.0 unit. 
Bradford Method 
The Bradford assay was performed according to Bradford (1976). In brief, 20µl of sample was 
added to 180µl of Bradford dye (0.5 mg/ml Coomassie Brilliant Blue G-250, 25% methanol, and 42.5% 
H3PO4) (Bio-Rad, Mississauga, ON) in a 96-well plate (Costar, Mississauga, ON) and incubated for 30 
minutes at room temperature. The absorbance at 595nm was measured with a microplate-reader 
(Molecular Devices, Sunnyvale, CA).  Samples were compared to a bovine serum albumin (BSA) standard 






The BCA assay was performed according to the manufacturer’s instructions (Thermo Scientific, 
Nepean, ON).  In brief, 100µl of sample (Diluted when necessary) was added to 100µl BCA dye, in a 96-
well plate (Costar, Mississauga, ON), and incubated at 37°C for 2 hours. The absorbance at 562nm was 
measured and corrected versus a solution containing only buffer.  Samples were compared to a BSA 
standard (Fisher, Nepean, ON) diluted in the same buffer as the samples. 
Activity Assays 
Prothrombin Times (PT) 
For this assay, 50µl normal human pooled reference plasma (NHP), 50µl HBS (20mM HEPES, 
150mM NaCl, pH 7.4), and 50µl thromboplastin (Trinity Biotech, Wicklow, Ireland) were added to 
removable strips (Nunc, Roskilde, Denmark) in a 96-well format.  The samples were then incubated at 
25°C for 1 minute with shaking between 15-25 seconds of the 1 minute incubation. Calcium chloride 
(50µl of 25mM) was then added to the sample(s). After a 15 second incubation at 25°C, the samples 
were agitated for 5 seconds, and the absorbance at 405nm was read every 5 seconds for 6 minutes in a 
microplate-reader (Molecular Devices, Sunnyvale, CA). PTs were determined as the time to reach the 
inflection point of the sigmoidal absorbance versus time curve produced. 
Activated Partial Thromboplastin Time (aPTT) 
For this assay, 50µl NHP, 50µl HBS, and 50µl aPTT reagent (bioMerieux, St Laurent, QC) were 
added to removable strips (Nunc, Roskilde, Denmark) in a 96-well format. The samples were then 
incubated at 25°C for 5 minutes, with 15 seconds of agitation during the 5 minute incubation, and 50µl 
of 25mM CaCl2 was then added to the samples. After a 15 second incubation at 25°C, the samples were 
agitated for 5 seconds, and the absorbance at 405nm was read every 5 seconds for 6 minutes in a 
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microplate-reader (Molecular Devices, Sunnyvale, CA). The aPPTs were determined as the time to reach 
the inflection point of the sigmoidal absorbance versus time curve produced. 
E. coli Protease Activity in the aPTT Assay 
For this assay, 60µl of concentrated E. coli culture supernatant was incubated with 60µl of NHP 
(Precision Biologicals, Halifax, NS) for 30 minutes at room temperature, and 100µl of the 120µl reaction 
was added to 50µl aPTT reagent (bioMerieux, St Laurent, QC)  and assayed in aPPT assay described 
above. 
E. coli Protease Activity Assay in Whole Blood 
For this assay, whole human blood (9 vol) was collected from a consenting volunteer (Male, 
25yrs) into 3.2% tri-sodium citrate (1vol) with a 20 gauge needle using a syringe (Becton Dickenson, 
Franklin Lakes, NJ). Concentrated E. coli supernatant (60µl) was incubated with 60µl of whole human 
blood for 30 minutes at room temperature. A portion of the 120µl  (100µl) reaction was added to 50µl 
thromboplastin (Trinity Biotech, Wicklow, Ireland), and 50µl 25mM CaCl2 reagent with a ball bearing in a 
4ml culture tube (Starstedt, Montreal, QC). The sample was agitated and repeatedly immersed in a 37°C 
water bath. Clot times were determined as the time after CaCl2 addition to retard ball bearing motility 
within the tube. All assays were performed within 1 hour of drawing the blood sample and citrated fresh 
blood was stored at room temperature until use.   
1-Stage FV Activity Assay in Human Plasma 
The FV microplate activity assay in human plasma has been described elsewhere (Tilley et al 
2011). 
FV deficient plasma was generated from normal human plasma according to (Blood et al 1979). 
Briefly, whole blood (9vol) was drawn from a consenting volunteer (Male, 50yrs) into tri-sodium citrate 
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(1vol) with a 20 gauge needle (Becton Dickenson, Franklin Lakes, NJ), and centrifuged twice at 3300 x g 
for ten minutes at room temperature. Cell-free plasma was collected, and EDTA was added to 5mM with 
gentle stirring at room temperature.  After correcting the pH to 7.4, the plasma was then incubated at 
37°C for approximately 14 hours. The prolongation of the prothrombin time was monitored every hour 
until it reached a stable maximal value. 
For this assay, 50µl of FV deficient plasma was added to 96-well microplate removable strips 
(Nunc, Roskilde, Denmark), followed by an addition of 50µl of 40-fold diluted NHP or sample plasma in 
HBS, and an addition of 50µl extensively dialyzed (1:100 20mM Tris, 150mM NaCl, pH 7.5) 
thromboplastin (Trinity Biotech, Wicklow, Ireland). The samples were then incubated at 25°C in a 
microplate-reader (Molecular Devices, Sunnyvale, CA) for 1 minute, with agitation for 10 seconds after 
the first 15 seconds of incubation. Calcium chloride (50µl of 25mM) was then added, and the samples 
were incubated for an additional 15 seconds at 25°C, followed by 5 seconds of agitation.  The 
absorbance at 405nm was read every 5 seconds for 6 minutes in a microplate-reader (Molecular 
Devices, Sunnyvale, CA). Clot times were determined as the time after CaCl2 addition to reach the 
inflection point of the sigmoidal absorbance versus time curve comprising the clot formation event.   A 
Log-Log standard curve of clot time versus FV activity was generated using serial dilutions of NHP in HBS.  
1U of FV activity was defined as the FV activity present in 1ml NHP. The initial rate of clot formation was 
determined using linear regression of the first 5 points after clotting was initiated. A Log-Log standard 
curve of initial rate versus FV activity was generated using serial dilutions of NHP in HBS. The extent of 
clot formation was determined as the maximal absorbance reading minus the minimal absorbance 
reading during the clot formation event. A standard curve of extent of clot formation versus FV activity 




2-Stage FV Activity Assay in Human Plasma 
For this assay, NHP or sample plasma was diluted 100-fold in HBS containing 2.83mM CaCl2 
(Final concentration).  Human thrombin was prepared according to Bajzar et al (1995) and was diluted in 
HBS and added to samples to give a final concentration of 0.5U/ml (Approximately 10nM).  After 
thrombin addition, the samples were incubated for 1 minute at 37°C.  The samples were briefly 
vortexed, and 50µl was assayed in the 1-stage FV Activity Assay in Human Plasma described above.  
E. coli Protease Activity versus FV in Human Plasma 
For this assay, 30µl of E. coli culture supernatant was incubated with 30µl of NHP diluted 5-fold 
in HBS, for 30 minutes at room temperature. The mixture was diluted an additional 4-fold in HBS (40-
fold final dilution with respect to NHP) and 50µl of the 40-fold diluted sample was assayed using 1-stage 
FV Activity Assay in Human Plasma described above. 
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
For this assay, 20-25µl of sample was added to 15-20µl 2x loading dye (LD; 0.025% bromophenol 
blue, 12.5% glycerol, 2% SDS, 5% β-mercaptoethanol, 10mM HEPES, 75mM NaCl) to a final volume of 
40µl.  The samples were incubated at 95°C for 5 minutes, and centrifuged at 4,000 x g for 4 seconds.  
The samples were loaded into polyacrylamide 4-20% gradient gels (Bio-Rad, Mississauga, ON) with 5µl-
20µl pre-stained molecular weight standards (Bio-Rad, Mississauga, ON) added to the two outer wells.  
The gels were electrophoresed at 150V constant voltage for approximately 1.5h, in 25mM Tris, 192mM 






Coomassie Brilliant Blue Staining for SDS-PAGE 
The gels were incubated in dilute CBB stain (0.01% CBB, 13% methanol, 5% acetic acid) for 
approximately 16 hours, at room temperature. The gels were de-stained for at least 1 hour in de-stain 
solution (19% methanol, 10% acetic acid) and photographed. 
Silver Staining for SDS-PAGE 
This procedure was modified from Merril et al (1981). Briefly, 200ml prefix solution (50% 
methanol, 10% ethanol, in water) was added to the gel and microwaved (Danby designer model) for 
1.5min at 50% power, the gel was removed during the 1.5 minute microwave step and shaken 
frequently at room temperature for approximately 10 seconds every 30 seconds. The gel was then 
incubated in the prefix solution at room temperature for 2 minutes with agitation.  The prefix solution 
was decanted, replaced with 200ml distilled water, and microwaved at 50% power with frequent 
shaking.  The gel was then incubated in distilled water at room temperature for 2 minutes with 
agitation.  The water was decanted and replaced with a solution of 100µM dithiothreitol (DTT solution) 
and then microwaved for 2 minutes at 50% power with frequent shaking.  The gel was then incubated in 
the DTT solution at room temperature for 2 minutes with agitation.  The DTT solution was decanted and 
replaced with silver nitrate solution (0.1% AgNO3 (w/v) in water) and microwaved for 1.5 minutes at 50% 
power with frequent shaking. The silver nitrate solution was decanted, and the gel was washed twice 
with 200ml of distilled water. Developer solution (200ml of 3% sodium carbonate, 0.019% 
formaldehyde) was added and incubated at room temperature with agitation until the protein bands 
reached a desirable intensity. The developer solution was then decanted and replaced with 10ml 2.3M 
citric acid and agitated for 1 minute to stop the reaction.  The citric acid solution was decanted, and the 
gel was washed with 200ml of distilled water.  The water was decanted and the gel was stored in 0.03% 




For this assay, 30µl of sample or HBS was incubated with 30µl NHP diluted 5-fold in HBS for 30 
minutes at room temperature. HBS (420µl) was then added, and the diluted samples (100µl) were added 
to 100µl of the 2x LD.  The samples were then incubated at 95°C for 5 minutes, and centrifuged at 4,000 
x g for 4 seconds. Samples (40µl) containing 0.25µl plasma were loaded into the wells of a 4-20% 
polyacrylamide gradient gel (Bio-Rad, Mississauga, ON). Pre-stained molecular weight standard (20µl) 
(Bio-Rad, Mississauga, ON) were added to each of the outer two wells.  The gel was electrophoresed at 
150V, constant voltage for approximately 1.5 hours in 25mM Tris, 192mM glycine, 0.1% SDS, pH 8.3.  
The gels were removed and electroblotted onto polyvinylidene fluoride (PVDF) Immobilon-P membranes 
(Millipore, Etobicoke, ON) at 35V constant voltage at 4°C with gentle stirring for approximately 16 hours 
in 25mM Tris, 192mM glycine, 0.05% SDS, 10% methanol, pH 8.3.  The PVDF membrane was then 
incubated in blocking buffer, 0.1% Tween-20 in Phosphate Buffer Saline (14mM NaCl, 1.5mM KH2PO4, 
10mM NaHPO4, 2.5mM KCl, pH 7.4) (PBSTW) containing 2% BSA (Fisher, Nepean, ON)  at room 
temperature for 1 hour with agitation.  The blocking buffer was then decanted and the PVDF membrane 
was washed 4x 5 minutes in 200ml washing buffer (PBSTW).  The final wash solution was decanted and 
replaced with 150ml primary antibody solution (198ng/ml (37,500-fold diluted) sheep anti-human 
Factor V IgG (Haematech, Burlington, VT), 5% (w/v) no-fat milk powder, in PBSTW) and incubated for 1 
hour at room temperature with agitation.  The primary antibody solution was decanted and the PVDF 
membrane was washed 4x 5 minutes in 150ml PBSTW, at room temperature.  The final wash solution was 
decanted and replaced with 200ml secondary antibody solution (30ng/ml (25,000-fold diluted) Donkey 
anti-Sheep IgG conjugated with horseradish peroxidase (Jackson Immunochemicals, West Grove, PA) in 
5% no fat milk powder in PBSTW). The secondary antibody solution was decanted and the PVDF 
membrane was washed 4x 5 minutes in 150ml PBSTW followed by a 150ml distilled water wash for 5 
minutes at room temperature.  The water was decanted and replaced with 10ml each of enhanced 
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chemiluminescence (ECL) reagent 1 and 2 (PerkinElmer, Waltham, MA) for 1 minute at room 
temperature with gentle stirring.  The PVDF membrane was then removed from the ECL solution, 
wrapped in plastic, and exposed to X-Ray film (Kodak, Toronto, ON) for various times at room 
temperature with an intensifying screen. The film was then developed with an automated developer 
(Kodak X-OMAT 1000A, Toronto, ON) and the image was scanned (Hewlett-Packard Scanjet 4750c 
scanner, Mississauga, ON). 
Column Chromatography 
Q-Sepharose Anion Exchange Chromatography 
Q-Sepharose (GE Healthcare, Baie d’Urfe, QC) (1-2ml) was prepared according to manufacturer’s 
instructions.  In brief, ethanol storage solution was decanted and replaced with running buffer (20mM 
HEPES, pH= 7.4 unless stated otherwise).  The gel matrix was agitated into a slurry, loaded into a 
column, and allowed to settle to a total bed volume of approximately 1-2ml. The matrix was 
equilibrated in at least 50 column volumes running buffer, “charged” in at least 25 column volumes 1M 
NaCl in running buffer, and re-equilibrated in at least 50 column volumes running buffer. Sample was 
then applied to the column and incubated for 0.5h at room temperature, or for 16h at 4°C. The column 
was washed with 10ml running buffer, and the sample was eluted in a continuous salt gradient from 0-
0.5M NaCl in running buffer (40ml total) at a flow rate of approximately 1.5ml/min.  The columns were 
then washed with 10ml 1M NaCl and/or 70% ethanol in running buffer to remove tightly bound 
material. The column was stored in 0.01% sodium azide at 4°C between uses. 
Sephadex G-100 Gel Filtration Column Chromatography 
Approximately 40ml of Sephadex G-100 matrix (Pharmacia, Uppsala, Sweden) was washed and 
slurried into a 1x40 cm column according to manufacturer’s instructions. The column was washed in at 
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least 100ml elution buffer (20mM Hepes, 150mM NaCl, 0.5M urea, 0.01% TritonX-100, 0.01% β-
mercaptoethanol) prior to applying the sample. The sample (600µl) was applied (1:67 ratio sample to 
column volume) to the column, and 500µl fractions were collected at a flow rate of 0.25ml/min at room 
temperature.   
Standard E. coli Culture Conditions 
Unless stated otherwise, E. coli O86a:K61 (ATCC 33985) was grown in 10ml minimal A (MA) 
minimal media (60mM K2HPO4, 33mM KH2PO4, 7.5mM ammonium sulphate, 1.7mM trisodium citrate, 
1mM MgSO4, 0.2% (w/v) glucose, pH 7.0), supplemented with 0.006% tryptone (Miller, 1992), overnight 
at 37°C, and sub-cultured (1% by volume) into 1L MA minimal media supplemented with 0.006% 
tryptone.  The 1L cultures were grown for approximately 16 hours at 37°C without agitation to an optical 
density (OD) at 600nm of approximately 0.6 ± 0.05 units. 
Standard E. coli Protease Purification 
E. coli O86a: K61 1L cultures were adjusted to pH 7.0, centrifuged (10,000xg, 30 minutes at 4°C) 
and 0.22µm filtered (Starstedt, Montreal, QC) to remove any remaining cells. The cell-free supernatant 
was concentrated from 1L to approximately 15ml using tangential flow filtration (TFF) (Pall, Mississauga, 
ON) with a 100kDa molecular weight cut off (MWCO) filter.  If required, the concentrated supernatant 
was buffer exchanged directly in the TFF system by the addition of 1.5L of desired buffer, and re-
concentration to 15ml.  After removal of the 15ml concentrate, the system was washed by the addition 
of another 15ml of desired buffer.  The solution was combined with the original 15ml concentrate, and 
concentrated further by centrifugal filter flow at 3,200 x g for 10 minutes at room temperature (CFF) 




E. coli Clinical Isolate Screen 
E. coli JM109, E. coli O86a: K61, and 6 E. coli clinical isolates (3 from rectum, 2 from urine, and 1 
from a wound), (Kindly provided by Helene Goulding, Medical Laboratory Science program, UOIT), were 
inoculated into 1mL Luria-Bertani broth (LB) overnight at 37°C 225rpm, streaked onto LB agar plates, 
and grown overnight at 37°C to confirm single colony morphology type. LB (50ml) was inoculated with a 
single bacterial colony from the plates and grown for 16h at 37°C 225rpm. Cells were removed by 
centrifugation at 10,000xg for 30 minutes at 4°C, and 0.22µm filtration (Millipore, Etobicoke, ON). The 
cell-free supernatant was concentrated from 50ml to 1ml using CFF on 100kDa MWCO filter (Millipore, 
Etobicoke, ON).  
Transmission Electron Microscopy (TEM) 
A 1L culture of E. coli O86a:K61 was grown in MA minimal media to an optical density of 
approximately 0.6 at 600nm. Cells were removed by centrifugation at 10,000xg for 30 minutes at 4°C 
and 0.22µm filtered (Starstedt, St. Leonard, QC).  The cell-free supernatant was concentrated from 1L to 
30ml using TFF with a 100kDa MWCO filter (Pall, Mississauga, ON), and further concentrated using CFF 
on 100kDa MWCO filters (Millipore, Etobicoke, ON) to 5ml. The concentrated material was 
ultracentrifuged at 150,000xg for 1.5h at 4°C and the pellet was suspended in 250µl HBS.  The re-
dissolved pellet was analyzed directly or after 100-fold dilution in HBS. The sample was applied to an 
ionized carbon-coated formvar film which was attached to a metal specimen grid for 30 seconds, and 
then washed with water for 30 seconds.  The sample was stained with 2% uranyl acetate, and washed 
again with water for 30 seconds prior to imaging. TEM imaging was performed at the Pathology & 





Samples were prepared according to Standard E. coli Protease Purification protocol (See above). 
The concentrated E. coli culture supernatant (5ml) was ultracentrifuged at 150,000xg for 1.5 hours at 
4°C. The ultracentrifuged concentrated E. coli culture supernatant was then concentrated to 1ml using 
CFF with a 100kDa MWCO filter (Millipore, Etobicoke, ON) and subjected to Sephadex G100 gel filtration 
column chromatography as described above. Fractions with the highest specific activity versus FV in NHP 
were pooled and concentrated 8-fold (800µl to 100µl) using CFF on a 10kDa MWCO filter (Millipore, 
Etobicoke, ON). The samples were added to an equal volume of 2x LD, and electrophoresed on 4-20% 
gradient polyacrylamide gels (Bio-Rad, Mississauga, ON) as described above in the SDS-PAGE section. 
The samples were then blotted onto PVDF membrane (Millipore, Etobicoke, ON) as described above in 
the Western blotting protocol; and stained with the Coomassie Brilliant Blue protocol for SDS-PAGE gels 
described above. The PVDF membrane was wrapped in plastic, thermo-sealed, and sent to the Advanced 
Protein Technology Centre at the Hospital for Sick Children (Toronto, ON) for N-terminal sequencing 
using the Edman degradation method (Edman, 1950). 
Statistical Analysis 






A typical depiction of the clot formation event in the FV coagulation assay over time generated 
by the microplate reader is shown in Figure 3. Visual inspection of the wells after the assay was 
performed confirmed that clot formation took place. All reactions produced a sigmoidal curve with a 
typical change in absorbance of 0.35-0.45 absorbance units at 405nm between the starting absorbance 
and maximal absorbance caused by the formation of fibrin. At least three parameters may be compared 
between samples. (1) The clot time was defined as the time to reach half the maximal change in 
absorbance (Approximately the inflection point of the absorbance versus time sigmoidal curve). (2) The 
initial rate was defined using linear regression of the first 5 time points after clotting is initiated in the 
linear portion of absorbance versus time sigmoidal curve. (3) The extent of clotting was defined as the 
maximal absorbance minus the initial absorbance of the sigmoidal absorbance versus time curve.  
To determine the FV clotting activity in a plasma sample, a standard curve of the time for clot 
formation versus FV 1-stage activity was generated using 2-fold serial dilutions of NHP into HBS. Fitting 
the Log-Log plot of clot time versus FV 1-stage activity demonstrated a strong linear relationship 
between these variables after regression analysis (r2 = 0.980) (Figure 4, Panel A). The relationship of clot 
time versus FV 1-stage activity remained linear in NHP diluted up to approximately 1024-fold. Fitting the 
Log-Log plot of initial rate versus FV 1-stage activity also demonstrated a strong linear relationship 
between these variables after regression analysis (r2 = 0.980) (Figure 4, Panel B).  Given that the FV 
concentration in NHP is approximately 12-40nM (Tracy et al 1982), the results indicate that the assay is 
sensitive to approximately 24-80pM FV in NHP. The results indicate that the normal range of FV activity 
in the FV 1-stage activity assay in 15 healthy controls (Male and female, aged 18-25) was approximately 
(Mean± Standard Deviation; Range): 0.96±0.14 U/ml; 0.68-1.11 U/ml. This result is similar to the FV  
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Figure 3 Monitoring Clot Formation in NHP with Kinetic Microplate FV 1-stage Coagulation Assay. 
Fibrin clot formation in NHP was monitored at 405nm over time in a microplate reader. The profile 
represents a typical microplate reader output of a 6 minute reaction of 32-fold diluted NHP. Readings 
were taken every 5 seconds. The y-axis denotes the change in absorbance at 405nm that occurred as a 
result of clot formation in plasma. The time of fibrin formation was defined as the time to reach the half 
maximal increase in absorbance (The inflection point; 36.4 seconds). The Initial rate of clot formation 
was defined as the rate of change of absorbance at 405nm over the first 5 time points of linear increase 
of absorbance (611.88 mUnits/min). The extent of clot formation was defined as the difference between 









Figure 4 Standard Curve of Time of Clot Formation versus Factor V Activity in NHP using FV 1-stage 
Microplate Assay. NHP was serially diluted (0- to 1024-fold in HBS) and assayed with the FV 1-stage 
microplate assay as described in text. Panel A denotes a Log-Log plot of the time of clot formation versus 
FV activity. Linear regression modelling of these results indicated a strong relationship between these 
variables (r2= 0.980). Panel B denotes a Log-Log plot of the initial rate of clot formation versus FV 
activity. Linear regression modelling of these results indicated a strong relationship between these 








































activity and range (0.66-1.14 U/ml) in healthy controls reported with automated analyzers (Cutler et al 
2010). A standard curve of the extent of clot formation versus FV 1-stage activity is also reported (Figure 
4, Panel C); however, given the parabolic nature of the curve, it was not suitable to calculate FV activity 
in a given plasma sample. 
Under the conditions of the assay using 40-fold diluted NHP, the intra-assay variability of the 
time of clot formation in the FV 1-stage assay among 6 wells on 8 different days was 3.4%. The inter-
assay variability of the time of clot formation in the FV 1-stage assay among 6 wells on 8 different days 
was 7.1%. Thus, the intra- and inter-assay variability of the FV 1-stage assay was at a low and acceptable 
level.  
The standard curve of clot time versus FV 1-stage activity (Figure 4, Panel A) was used to 
measure the FV activity in nine DIC patient plasmas which were (FV 2-stage activity) or were not (FV 1-
stage activity) intentionally activated with added thrombin. The extent and initial rate of clot formation 
was also analyzed (Table 1). All nine DIC patient plasmas exhibited FV 1-stage activities and initial rates 
that were decreased on average by 54% and 18%, respectively, from NHP. The extents of clot formation 
in the FV 1-stage assay in the DIC patients were not largely different from NHP, and increased on 
average by approximately 13% from NHP. 
Activation of NHP with thrombin generated an approximate 8-fold increase in FV 2-stage activity 
above the FV 1-stage activity (Table 1). This indicates that the FV in NHP was mainly present in its 
inactive procofactor form which is consistent with results published by other investigators (Nesheim et 
al 1981). The FV 2-stage and total activity (2-stage FV activity - 1-stage FV activity) were also decreased 
in the DIC patients on average by approximately 44% and 42%, respectively, from NHP. The initial rates 
and extents of clot formation in the 2-stage assay in the DIC patients were not largely different from 
NHP, and varied on average by approximately 9% and 4%, respectively, from that observed with NHP. 
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Table 1 FV Functional Activity in NHP and in 9 Patients Who Developed DIC. The FV 1-stage, 2-stage, 
and total activity in NHP and 9 DIC patient plasma samples were determined from the FV 1-stage 
microplate assay standard curve of time of clot formation versus FV activity. Also presented are the 




Table 1.  
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To analyze the prevalence of E. coli strains which secrete proteases capable of cleaving and 
inactivating FV, 50-fold concentrated (CFF with a 100kDa MWCO filter) cell-free supernatants from 
JM109, O86a:K61, and 6 E. coli clinical isolates from Lakeridge Healthcare (Oshawa, ON) were subjected 
to FV Western Blotting (Figure 5). Also, the 100kDa filtrate from E. coli O86a:K61 was concentrated using 
centrifugal filter flow with a 10kDa MWCO filter (O86a: K61 FT) and analyzed. Two of six E. coli clinical 
isolates (Wound, and 2 Rectum) secreted a protease which was retained on a 100kDa filter and was 
capable of cleaving FV, again to a 250kDa product. Curiously, the laboratory strain E. coli JM109 also 
demonstrated the ability to cleave and inactivate FV in NHP. E. coli O86a: K61 culture supernatant 
100kDa retenate, but not filtrate, was capable of cleaving and inactivating FV. This result agrees with 
data obtained from the E. coli protease activity versus FV in plasma assay where 95% of the protease 
activity was retained by the 100kDa filter (Data not shown).    
To measure the E. coli secreted protease activity, a standard curve of FV 1-stage clot time versus 
protease activity (Figure 6) was generated using 2-fold serial dilutions in HBS of 500-fold concentrated E. 
coli culture supernatant.  A rectangular 3-parameter non-linear regression indicated a strong 
relationship between these variables between 8-fold and 512-fold dilution points (r² = 0.993). At least 
one protease standard curve was generated for every culture preparation from the TFF 100kDa 
retenate. 1 unit of protease activity was defined as the activity present in 1ml 500-fold concentrated E. 
coli supernatant. 
The effect of 500-fold concentrated E. coli supernatant on FV activity in NHP was measured 
using the FV 1-stage activity assay (Figure 7). In the presence of 0.1% β-mercaptoethanol the time of clot 
formation was increased on average by 55.2 seconds, compared to NHP treated with buffer. FV activity 
was determined using a FV standard curve (Figure 4). In samples treated with concentrated E. coli  
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Figure 5 Effects of Concentrated Supernatants from E. coli Strains JM109, O86a: K61, and 6 Clinical 
Isolates on FV by Western Blot. LB overnight E. coli cultures (50ml) supernatants of strains JM109 
(Laboratory strain), O86a:K61, and 6 E. coli clinical isolates were concentrated as described in the text, 
and exposed to NHP. NHP (0.25µl) was loaded per well in 4-20% polyacrylamide gradient gels, and 
electrophoresed for 1.5h at 150V, constant voltage. Proteins were electroblotted onto a PVDF 
membrane for 16 hours at 35V, constant voltage, and were probed with sheep anti-human Factor V IgG, 
and then donkey anti-sheep IgG conjugated with HRP. See materials and methods for complete 
description of Western Blotting protocol. “NHP” refers to plasma which was treated with buffer alone. 




































































Figure 6 Standard Curve of Time of Clot Formation versus E. coli Protease Activity in NHP using FV 1-
stage Microplate Assay. E. coli concentrated culture supernatant was serially diluted (8- to 512-fold in 
HBS) and incubated with 5-fold diluted NHP in HBS for 30 minutes at room temperature. The sample 
was further diluted 4-fold (40-fold final with respect to NHP) and assayed with the FV 1-stage microplate 
assay described in text. The curve was generated using a rectangular 3-parameter non-linear regression 




























Figure 7 Effect of Concentrated E. coli Supernatant on FV Activity in NHP. Concentrated E. coli 
supernatant (500-fold) was prepared according to standard enzyme preparation described in text, and 
incubated with NHP according to E. coli protease activity assay versus FV described in text. FV activity 
was determined using FV 1-stage clot times and the FV standard curve (Fig. 4). FV activity was 





































culture supernatant, FV activity was significantly decreased (Rank Sum Test, p = 0.026) to (Mean± 
Standard Deviation) 15% ± 0.34% (n=4), compared to the HBS buffer control. E. coli supernatant 
required concentration for accurate measurement of protease activity. Concentrated culture media 
without E. coli had no effect on FV activity in NHP, indicating that the inactivation effect required a 
component from growing bacterial cells which is released into the culture medium. 
The effect of 500-fold concentrated E. coli supernatant on the initial rate of clot formation in 
NHP was measured using the FV 1-stage activity assay (Figure 8). The initial rate of clot formation was 
not significantly different (Paired t-Test, p = 1.0) in NHP treated with concentrated E. coli supernatant 
(Mean ± Standard Deviation) 334 mU/min ± 23mU/min, compared to NHP treated with buffer (Mean ± 
Standard Deviation) 334 mU/min ± 28mU/min (n=4).  
The effect of 500-fold concentrated E. coli O86a:K61 supernatant on the extent of clot formation 
in NHP was measured using the FV 1-stage activity assay (Figure 9).  The extent of clot formation was 
increased on average by 0.051 absorbance units (a405nm), compared to NHP treated with buffer. The 
extent of clot formation was significantly increased (t-test p < 0.001) to (Mean ± Standard Deviation) 
111% ± 1% (n=4) compared to NHP treated with HBS. 
The effect of 500-fold concentrated E. coli supernatant on the time of clot formation in whole 
human blood was measured using the E. coli protease activity versus whole blood assay (Figure 10). The 
time for clot formation was significantly increased (Paired t-Test, p = 0.047) when whole blood was 
treated with concentrated E. coli supernatant compared to samples treated with HBS. The time for clot 
formation was (Mean ± Standard Deviation) 41.3s ± 4.3s in samples treated with concentrated E. coli 
supernatant, compared to (Mean ± Standard Deviation) 35.8s ± 4.1s in buffer controls (n=6). 
The effect of 500-fold concentrated E. coli supernatant on the time of clot formation was 
measured using the E. coli protease activity in aPTT assay (Figure 11). The time for clot formation was  
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Figure 8 Effect of Concentrated E. coli Supernatant on Initial Rate of Clot Formation in NHP. 
Concentrated E. coli O86a:K61 supernatant (500-fold) was prepared according to standard enzyme 
preparation described in text and incubated with NHP according to E. coli protease activity assay versus 
FV described in the text. The initial rate of clot formation was determined as described in Figure 1. The 
initial rate of clot formation was not significantly different in samples treated with concentrated E. coli 




































Figure 9 Effect of Concentrated E. coli Supernatant on Extent of Clot Formation in NHP. Concentrated 
E. coli O86a:K61 supernatant (500-fold) was prepared according to standard enzyme preparation 
described in text, and incubated with NHP according to E. coli protease activity assay described in text. 
The extent of clot formation was determined as described in Figure 3. The extent of clot formation was 
significantly increased in samples treated with concentrated E. coli supernatant compared to samples 









































Figure 10 Effect of Concentrated E. coli Supernatant on Time of Clot Formation in Whole Human 
Blood. Concentrated E. coli O86a:K61 supernatant (500-fold) was prepared according to standard 
enzyme preparation and incubated with whole human blood according to E. coli protease activity assay 
versus whole blood described in text. The time of clot formation was determined as the time to retard 
ball bearing motility within the reaction tube. Concentrated E. coli supernatant significantly increased 





































Figure 11 Effect of Concentrated E. coli Supernatant on Time of Clot Formation using aPTT Assay in 
NHP. Concentrated E. coli O86a:K61 supernatant (500-fold) was prepared according to standard enzyme 
preparation and incubated with NHP according to E. coli protease activity assay versus aPTT as described 
in text. The time of clot formation was determined as described in Figure 3. Concentrated E. coli 
supernatant significantly increased the time for clot formation compared to samples treated with buffer 
































significantly increased (Paired t-Test, p = 0.019) when NHP was treated with concentrated E. coli 
O86a:K61 supernatant, compared to samples treated with buffer alone. The time for clot formation was 
(Mean ± Standard Deviation) 84.3s ± 10s when NHP was treated with concentrated E. coli supernatant, 
compared to (Mean ± Standard Deviation) 62.2s ± 2s in buffer controls (n=3). 
The effects of PMSF and A1PI on 500-fold concentrated E. coli supernatant were measured using 
the E. coli protease activity assay versus FV in NHP (Figure 12). E. coli protease activity was significantly 
reduced to (Mean ± Standard Deviation) 12.5% ± 5.1% of buffer control treated E. coli protease, after a 
10 minute incubation with 1.5mg/ml A1PI at room temperature (n=3, Paired T-test p<0.001). A1PI at 
1.5mg/ml had no significant effect on clot formation by itself, indicating that this inhibitory effect was 
directed at the E. coli protease; and not the coagulation factors during the microplate assay. E. coli 
protease activity was reduced to (Mean ± Standard Deviation) 75.7% ± 3.7% after a 1 hour incubation 
with 1.5mM PMSF at room temperature, compared to samples incubated with PMSF diluent alone. 
PMSF is an irreversible serine protease inhibitor that is extremely unstable in solutions of neutral pH, 
becoming completely inactive after 1 hour at room temperature. Therefore, a 1 hour incubation at room 
temperature was sufficient to prevent interference with the serine proteases of the coagulation system 
in the FV activity assay. The E. coli protease retained all of its activity after 30 minute incubations with 
1mM tetracycline (Metallo protease inhibitor), 1mM N-[N-(L-3-transcarboxyirane-2-carbonyl)-L-Leucyl]-
agmatine (E64) (Irreversible cysteine protease inhibitor), or 2mM iodoacetamide (Irreversible cysteine 
protease inhibitor) (Data not shown). The inhibitors alone had no effect on the FV activity assay 
indicating specificity for the E.coli protease. All inhibitor concentrations used were at or above the 
maximum suggested concentration recommended by the manufacturer.  Tetracycline was used at the 
highest concentration tolerated by the activity assay which was comparable to the concentrations 




Figure 12 Effects of Protease Inhibitors on Concentrated E. coli Protease against FV Activity in NHP. 
Concentrated E. coli O86a:K61 supernatant (500-fold) was prepared according to standard enzyme 
preparation described in text, and incubated with equal volumes of 3 mg/ml alpha 1-protease inhibitor 
(A1PI; Calbiochem, LaJolla, CA) for 10 minutes (Panel A) or 3mM phenylmethylsulfonyl fluoride (PMSF) 
for 1 hour (Panel B). After incubation, samples were assayed using E. coli protease activity assay versus 
FV described in text. Activities were generated using the E. coli protease standard curve (Fig. 5) and 
















































































Figure 13 Effect of Divalent Cations on Concentrated E. coli Protease Activity in NHP. Concentrated E. 
coli O86a:K61 supernatant (500-fold) was prepared according to standard enzyme preparation described 
in text, and incubated with equal volumes 1mM ZnS04, CuSO4, FeCl2, or HBS for 10 minutes at room 
temperature. After incubation, samples were assayed using E. coli protease activity assay versus FV 





































The effects of various divalent cations on 500-fold concentrated E. coli supernatant were 
measured using the E. coli protease activity assay versus FV (Figure 13) and compared to an E. coli 
protease standard curve (Figure 6). E. coli protease activity was (Mean ± Standard Deviation) 49% ± 11%, 
34% ± 13%, or 104% ± 2% of untreated samples after 10 minute incubations at room temperature with 
0.5mM ZnS04, CuSO4, or FeCl2, respectively, (n=3). 
The heat stability of 500-fold concentrated E. coli supernatant was analyzed using the E. coli 
protease activity assay versus FV (Figure 14) and compared to an E. coli protease standard curve (Figure 
6). The E. coli protease was stable at 80°C for up to 1 hour (Figure 14, Panel A), retaining (Mean ± 
Standard Deviation) 99% ± 40%, 99% ± 7%, and 108% ± 7% activity after 10 minutes, 30 minutes, and 1 
hour at 80°C, respectively, compared to samples which were incubated at room temperature. The E. coli 
protease was somewhat susceptible to heat inactivation at 95°C (Figure 14, Panel B), retaining (Mean ± 
Standard Deviation) 87% ± 2%, 46% ± 3%, and 65% ± 8% activity after 10 minute, 1 hour, or 3 hour 
incubations, respectively, at 95°C. The E. coli protease was also stable for up to 1 hour at 70°C, and 
retained (Mean± Standard Deviation) 71%± 22% activity after 3 hour incubations at 70°C, compared to 
samples incubated at room temperature (Data not shown). Curiously, no protein visibly precipitated out 
of the solution after heating for up to 3 hours at up to 95°C (Data not shown). 
A typical protease elution profile upon Sephadex G-100 gel filtration chromatography is shown 
in Figure 15. Approximately 82% of the E. coli protease activity applied to the column was recovered, 
and approximately 150% of the protein applied to the column was recovered. This was most likely due 
to protein concentration flanking the main protein peak being lower than the ideal detection limit of the 
a280nm assay. The E. coli protease specific activity was increased by approximately 3-fold (1.48mg/ml 
applied to column to 4.27mg/ml in fraction 18), which may be a conservative estimation due to the 
overestimation of protein concentration. Analysis of fraction 18 by SDS-PAGE with Coomassie Brilliant 
Blue staining revealed two proteins with apparent molecular weights of 37kDa and 90kDa (Figure 16).   
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Figure 14 Thermal Stability of Concentrated E. coli Protease Activity against FV in NHP. Concentrated E. 
coli O86a:K61 supernatant (500-fold) was prepared according to standard enzyme preparation described 
in text, and incubated at 80°C (Panel A) or 95°C (Panel B) for various times. After incubation, samples 
were assayed using E. coli protease activity assay versus FV. Activities were generated using the E. coli 















































































Figure 15 Sephadex G-100 Gel Filtration Chromatography of E. coli Concentrated and Ultracentrifuged 
Culture Supernatant. Ultracentrifuged supernatant (600µl) was applied to a Sephadex G-100 column, 
and eluted in the same buffer as the sample (20mM Hepes, 150mM NaCl, 0.5M urea, 0.01% TritonX-100, 
0.01% β-mercaptoethanol) at room temperature collecting 500µl fractions with a flow rate of 
0.25ml/min. Protein concentrations (Circles) were calculated using the a280nm method described in 
text. E. coli protease activities versus FV in plasma (Squares) were calculated as described in text and 
compared to a protease standard curve (Fig. 5). See Materials and Methods for complete description of 























































Figure 16 SDS-PAGE with Coomassie Brilliant Blue Staining of Protein Purification by TFF Filtration, 
Ultracentrifuge Separation, and Sephadex G-100 Column Chromatography. TFF Filtrate refers to TFF 
10kDa MWCO concentrated filtrate after TFF 100kDa MWCO concentration. Ultracentrifuge pellet refers 
to the material that formed a pellet after 150,000 x g for 1.5h at 4°C. Ultracentrifuge supernatant is the 
material that remained soluble after ultracentrifugation. Ultracentrifuge supernatant was concentrated 
using CFF with a 10kDa MWCO filter, and applied to a Sephadex G-100 column (40ml bed volume). F14 
(Fraction 14)-F38 (Fraction 38) are column elution fractions.  See Figure 15 for complete column elution 
profile. Each sample (25µl) was loaded per well of a 4-20% polyacrylamide gradient gel, and 
electrophoresed at 150V, constant voltage. The gel was stained with 0.01% Coomassie Brilliant Blue, and 












































































Figure 17 SDS-PAGE with Silver Staining of Protein Purification by TFF Filtration, Ultracentrifuge 
Separation, and Sephadex G-100 Column Chromatography. TFF Filtrate refers to TFF 10kDa MWCO 
concentrated filtrate after TFF 100kDa MWCO concentration. Ultracentrifuge pellet refers to the 
material that formed a pellet after 150,000 x g for 1.5h at 4°C. Ultracentrifuge supernatant is the 
material that remained soluble after ultracentrifugation. Ultracentrifuge supernatant was concentrated 
using CFF with a 10kDa MWCO filter, and applied to a Sephadex G-100 column (40ml bed volumn). F14 
(Fraction 14)-F38 (Fraction 38) are column elution fractions.  See Figure 15 for complete column elution 
profile. Each sample (25µl) was loaded per well of a 4-20% polyacrylamide gradient gel and 
electrophoresed at 150V, constant voltage. The gel was stained silver (Mullin et al 1981), and 
photographed. See Materials and Methods for complete description of SDS-PAGE and silver staining 

































































The non-symmetrical elution peak of activity may correlate with the presence of a third protein, seen in 
fraction 22 (and subsequent fractions) with an apparent molecular weight of approximately 110kDa. 
Analysis by SDS-PAGE with Silver staining (Figure 17) revealed large blurry bands in the 10-25kDa region 
of the gel and a distinct banding ladder in the 37-75kDa region, which may correlate to rough 
lipopolysacharide (LPS) or intact O-antigen of LPS, respectively, reported by others (Haurat et al 2010). 
LPS will stain with silver, but not by CBB staining (Haurat et al 2010). The purification table (Table 2) 
shows an approximate 1000-fold increase in specific activity compared to cell-free culture supernatant, 
with specific activity increases of 74-fold, 329-fold after TFF concentration, and ultracentrifugation, 
respectively. The protocol yielded approximately 8.5% of E. coli protease activity present in the TFF 
100kDa retenate. The Sephadex G-100 gel filtration fractions which showed activity in the E. coli 
protease activity versus FV in NHP assay were subjected to Western blotting versus FV in NHP (Figure 
18). A 10-fold dilution of the material applied to the column (Column SM; starting material; 10xdil), and 
all fractions which inactivated FV in the activity assay were also capable of cleaving intact FV (330kDa) to 
an inactive 250kDa product. Curiously, the 250kDa FV cleavage product produced by the E. coli protease 
cleavage is more intense than the intact 330kDa FV molecule.  
To better understand the unusual elution profile from the Sephadex G-100 gel filtration column, 
the ultracentrifuged pellet (Containing 45% of the activity seen in the ultracentrifuge supernatant used 
in the column) was analyzed using negative staining (2% uranyl acetate) and transmission electron 
microscopy (Figure 19). A total of 9 images were analyzed to determine the size of the vesicles (n=2048) 
which were heterogeneous in nature. The maximum diameter of OMVs observed was 158nm, which is 
below the theoretical maximum of 200nm imposed by the 0.2µm filtration step used to remove any 
whole cells remaining after centrifugation of the bacterial culture. It is possible that E. coli O86a:K61 
secretes larger OMVs; however, the protocol used here would not allow for their detection. The  
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Table 2 Purification Table of Protein Isolation Procedure. Culture supernatant refers to cell-free culture 
supernatant described in text. TFF 100kDa retenate refers to TFF 100kDa MWCO filter concentrated 
material  and centrifugal filter flow 100kDa MWCO filter concentrated material (Total concentration 1L 
to 5ml). Ultracentrifugation refers to CFF 10kDa MWCO filter concentrated ultracentrifuge supernatant 
(5ml to 1ml). Gel Filtration refers to Sephadex G-100 gel filtration elution fractions with the highest E. 
coli protease-specific activities which were pooled and concentrated using CFF 10kDa MWCO filter. 
Activities were determined using E. coli protease activity assay versus FV and an E. coli protease 
















900 45 N/A 
TFF 100kDa 
Retenate 
1380 335.7 74 
Ultra-
centrifugation 
1000 1490 329 






Figure 18 Western Blot for FV of Sephadex G-100 Gel Filtration Fractions. NHP refers to HBS treated 
plasma. F17 (Fraction 17)-F26 (Fraction 26) are Sephadex G-100 gel filtration eluted fractions (See Figure 
14). Column SM (Starting material; 10x dil) is a 10-fold dilution of the material that was applied to the 
column, which was concentrated ultracentrifuged supernatant. Plasma (0.25µl) was loaded per well in 4-
20% polyacrylamide gradient gels and electrophoresed for 1.5h at 150V constant voltage. Proteins were 
electroblotted onto a PVDF membrane for 16 hours at 35V constant voltage and were probed with 
sheep anti-human Factor V IgG and donkey anti-sheep IgG with conjugated HRP. See materials and 
methods for complete description of Western Blotting protocol. “NHP” refers to plasma which was 
























Figure 19 Transmission Electron Micrographs of Negative Stained E. coli O86a: K61 Outer Membrane 
Vesicles. OMVs were isolated as described in the text and negatively stained with 2% uranyl acetate at 
the Hospital for Sick Children (Toronto, ON). Panel A depicts 4000-fold concentrated OMVs at 62,000 x 
magnification. Panel B depicts 4000-fold concentrated OMVs at 120,000 x magnification. Panel C and D 










minimum diameter of OMVs observed was 8nm, which is smaller than the expected 20-250nm range 
reported by others (Kulp and Kuehn 2010).  However, OMVs of 8nm diameter would be expected to be 
retained by the approximately 5nm pore size of a 100kDa filter. The average diameter of the OMVs was 
(Mean ± Standard Deviation) 21nm ± 13nm. Figure 19, Panel A, depicts several large vesicles, with 
smaller vesicles constituting the majority of the background (62,000x magnification). Panel B shows a 
close-up of the smaller vesicles seen in Panel A (120,000x magnification). To ensure the smaller vesicles 
were not artefactual, a 100-fold dilution was made to allow for the detection of background grid staining 
(Panel C and D). These images show smaller vesicles in contrast to the background grid (150,000x 
magnification).  
In an attempt to further purify the E. coli protease from the OMVs, various detergents, reducing 
agents, and solubilising reagents were screened for their effect on the 1-stage FV activity assay, and on 
the E. coli protease activity (Table 3). Although the 1-stage FV activity assay could tolerate 
concentrations above the critical micelle forming concentration (Cmc) of several detergents, the E. coli 
protease would not tolerate detergent concentrations at or above the Cmc of any detergent. This 
implies that the protease may require intact OMVs for function.  Curiously, reducing agents such as β-
mercaptoethanol and DTT significantly enhanced the protease activity (at 0.1%) by up to 500-fold, which 
would be consistent with the secreted E. coli protease belonging to a cysteine protease family (Yang et 
al 2011). However, as discussed above, the E. coli protease was not inhibited by cysteine protease 
inhibitors. Urea also enhanced activity by 2-fold at concentrations up to 1M; however, the FV activity 
assay would not tolerate urea concentrations in excess of 1M.  
The effects of detergent solubilisation with 30mM CHAPS on protein binding to a Q-Sepharose 
anion exchange column was analyzed in Figure 20. Without a solubilising reagent, the proteins present 
in the E. coli supernatant would not bind to Q-Sepharose anion exchange columns at pH 7.4, and eluted 
immediately in fraction 1 (Panel B). The same effect was observed when the column was run at pH 8.0  
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Table 3 The Effects of Detergents on FV 1-stage Activity Assay and on E. coli Protease Activity. Various 
ionic and non-ionic detergents, reducing agents, and urea were screened for their effects on the 1-stage 









Reagent Tolerated by 
Activity Assay 
Reduction in 
Protease Activity  
Tween 20 1% 100% 
Tween 80 1% 100% 
TritonX-100 1% 100% 
β-Mercaptoethanol 0.1% ~500-fold Activation 
Urea 1M ~2-fold Activation 
SDS 0.00001% N/A 
N-Lauroylsarcosine <0.01% N/A 
Dithiothreitol (DTT) 0.1% ~500-fold Activation 





Figure 20 SDS-PAGE with Silver Staining of Fractions from Q-Sepharose Anion Exchange 
Chromatography. UC sup, refers to ultracentrifuge supernatant (See also in Fig. 16-17). Column SM 
depicts centrifugal filter flow 10kDa MWCO filter concentrated ultracentrifuged supernatant. F1 
(Fraction 1) –F52 (Fraction 52) (Panel A) are eluted fractions. The column was run in 20mM Hepes pH 7.4 
(Panel B), or with 20mM Hepes pH 7.4 with 30mM CHAPS (Panel A). Protein bound to the column in the 
presence of 30mM CHAPS (Panel A), but did not bind in the absence of 30mM CHAPS (Panel B). “+” 
indicates protease activity by E. coli protease activity assay versus FV, and “-“ indicates no detectable 
activity. The binding buffer contained 30mM CHAPS, the elution buffer did not contain CHAPS (Panel A). 
Each sample (25µl) was loaded per well of a 4-20% polyacrylamide gradient gel and electrophoresed at 
150V constant voltage. The gel was stained with silver (Mullin et al 1981) and photographed. See 
Materials and Methods for complete description of SDS-PAGE, and silver staining protocol. Molecular 









(Data not shown). No protein or protease binding was observed with SP-Sephadex cation exchange 
chromatography at pH 5.5, 7, or 8 (Data not shown), or with Benzamidine Sepharose chromatography 
(Serine protease affinity column; data not shown). Solubilisation with 30mM CHAPS promoted protein 
binding to the column; however, 30mM CHAPS interfered with the FV activity assay, necessitating 
elution in the absence of CHAPS. A single protein eluted from the column in fraction 19 (At 
approximately 112.5mM NaCl) (Panel A), but no protease activity versus FV was associated with this 
eluted protein. A protein of the same molecular weight also eluted in fraction 51 and 52 at 1M NaCl, 
along with several low molecular weight species which were consistent with rough LPS. Fraction 51 and 
52 demonstrated activity (Approximately 20% of the protease activity applied to the column) in the E. 
coli protease activity versus FV in human plasma assay; however, it is unclear if CHAPS was present in 
the sample, which would interfere with the measurement. Also, the NaCl concentration (1M) used to 
elute the protein from the Q-Sepharose bedding interfered with the activity assay; therefore, a 
correction value was used to estimate the protease activity. The majority of the protein which bound to 
the column did not elute after 1M NaCl wash and would not elute until the application of 70% ethanol; 
however, 70% ethanol is not compatible with any of the assays used in this study.   
Given the inability to fractionate the protein sample beyond the conditions used in Table 2, the 
3 major proteins which were associated with the OMVs that displayed protease activity versus FV in the 
microplate assay were N-Terminally sequenced (Table 4). Sequence data for the 90kDa and 110kDa 
protein could not be obtained due to insufficient protein concentration or the proteins being N-
terminally blocked. The 37kDa protein generated sequencing data which was compared to the Swiss-
Prot protein database. The DXVYNKDG (Where X is an unknown amino acid) sequence was reduced to 
VYNKDG (Most confidence), and compared with other known proteins of E. coli. Although a 6 amino acid 
sequence was insufficient to conclusively identify the sequenced protein, several candidate proteins 
have been identified. YedS (Theoretical protein), Outer membrane protein C (OmpC), Outer membrane  
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Table 4 N-Terminal Sequencing of Sephadex G-100 Gel Filtration Fractions with the Highest Protease 
Specific Activity. Purification table was described in Table 2 and SDS-PAGE was described in Figure 16-
17. Sephadex G-100 fractions 17-19 were pooled and concentrated 8-fold by centrifugal flow filtration 
with a 10kDa MWCO filter. The samples were run on SDS-PAGE described in text and electroblotted 
onto PVDF membrane described in text. The samples were then sent for N-Terminal sequencing at the 
Hospital for Sick Children Advance Protein Technology Center (Toronto, ON). The 1 letter 8 amino acid 
sequence was modified to 6 amino acids and compared against the Swiss-Prot data base. X designates 
unknown amino acid. Bolded letters are “positive” hits, and underlined letters are “negative” hits. 
Numbers before or after the amino acid sequence refer to the amino acid position within the translated 






37kDa N-terminal Sequence: DXVYNKDG  
BLAST Sequence: VYNKDG  
Protein (Name) Sequence Identity (%) Positives (%) Function 
YedS 24VYNKDG29 100 100 porin 
OmpC 24VYNKDG29 100 100 porin 
OmpN 24VYNKDG29 100 100 porin 
YddL 24VYNKDG29 100 100 porin 
OmpF 25IYNKDG30 83 100 porin 
Pic 86VYDKDG91 83 100 serine protease 
Pic 854VYLTDG859 67 67 serine protease 





protein N (OmpN), YddL(Theoretical protein), and Outer membrane protein F (OmpF) are all porins 
which have molecular weights that are consistent with the predicted molecular weight (37kDa) based on 
SDS-PAGE (Figure 13 and 14), and produced 100% positive sequence alignments. OMV associated porins 
have been described for other gastro-pathogenic bacteria (Mullaney et al 2009); however, they would 
not be expected to have proteolytic activity. Also identified was Pic, an E. coli SPATE, which other 
investigators have demonstrated has proteolytic activity towards FV (Dutta et al 2002); however, Pic has 
a molecular weight of >100kDa. Two separate regions within Pic produced positive alignments, one near 
the N-terminal end (100% positive), and one near the middle of the protein (67% positive). Pic has not 
been reported to associate with OMVs. Hemoglobin protease (Hbp), another E. coli SPATE, also showed 
some (67% positive) sequence alignment similarities; however, this protease has not been reported to 
cleave FV (Dautin 2010), nor has it been reported to associate with OMVs. It is currently unclear 





The kinetic microplate-based assay outlined here describes the development of a new, fast, 
economical, and simple technique for measurement of FV coagulation activity in samples of human 
plasma which have or have not been intentionally activated by thrombin.  Development of this assay 
was critical to the success of this study as it allowed for the quantification of E. coli protease activity 
against FV. The assay measures the increase in turbidity of plasma during clot formation at 405nm using 
a kinetic microplate-reader. The assay also has the added advantage of using small sample volumes 
(50µl) as well as being able to analyze multiple samples simultaneously (up to 12). These assay 
characteristics are advantageous when expensive reagents are required (Such as factor-deficient 
plasmas), or when only small sample volumes are available (Such as clinical patient plasmas). The assay’s 
speed allows for the analysis of a large number of samples, which is necessary during FV protein 
purification procedures from human or animal plasma, or when purifying proteins which 
activate/inactivate FV coagulation activity.   
The results indicate that the FV in the DIC patient plasmas was functionally less active than NHP 
because of prolonged clot times and decreased initial rates of clot formation in the FV 1-stage assay. 
However, the initial rates of clot formation in the FV 2-stage assay in the DIC patients were not largely 
different from NHP.  The extents of clot formation in the DIC patient plasmas were also not largely 
different from NHP in the FV 1-stage and 2-stage assays.  The unchanged extent of clot formation in the 
DIC patients may be attributed to non-FV coagulation factor levels, such as fibrinogen in the FV-deficient 
plasma and may be unrelated to characteristics of the patient plasmas.  
The FV in the DIC patient plasmas supported both a delayed and slower rate of fibrin clot 
formation compared with NHP.  Compared with NHP, the FV 1-stage, FV 2-stage, and total (FV 2-stage 
activity – FV 1-stage activity) activities in the DIC patient plasma were decreased on average by 
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approximately 54%, 44%, and 42%, respectively. The decreased FV 1-stage, 2-stage, and total activities 
may have been due to increased FV consumption (Mammen 2000) and/or inactivation (Samis et al 2004) 
which occurred during the pathogenesis of this acquired blood disorder in the patients studied. In 
previous studies with patient plasmas, it was demonstrated that DIC patient FV antigen levels were not 
significantly different from NHP (Samis 2011, unpublished observations); however, inactivation of FV by 
host and/or pathogen proteases may allow for increased epitope recognition by antibodies in the 
absence of functional FV activity.  
The results of the microplate assay indicate that measurement of FV coagulation activity in 
human plasma samples may be obtained from the time and initial rate measurements of clot formation 
from the FV 1-stage assay, and the time of clot formation and total activity measurement from the FV 2-
stage assay. It was, however, not possible to obtain a quantitative measurement of FV coagulation 
activity in a plasma sample based on the extent of clot formation in the FV 1- and 2-stage assay, or the 
initial rate of clot formation in the FV 2-stage assay. During the production of a typical FV activity 
standard curve, the extent of clot formation decreases initially upon serial dilution of NHP; however, 
subsequent dilutions of NHP result in an increase in the extent of clot formation. Initially, the decrease 
in extent may be attributed to decreasing levels of a FV activator of this process in NHP. The fact that 
the extent of clot formation increases after further dilution of NHP may represent the real effect of 
decreasing FV concentrations on clot formation and/or dilution of a FV inhibitor of this process in NHP. 
This increase in extent of clot formation as FV coagulation activity decreases may be a compensation 
mechanism employed by the host in the event of FV consumption or inactivation during pathological 
states; however, further studies are needed to confirm these speculations. 
E. coli represents a major health threat despite being the most heavily studied life form, and is 
one of the most important clinically relevant pathogens. E. coli is the second most frequently isolated 
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pathogen from bloodstream infections (Kern 2011) accounts for up to 9% of ventilator associated 
pneumonia episodes in Canada (Cook et al 1998), 8% of surgical site infections in the US (National 
Nosocomial Infections Surveillance System, 1996), and over 850,000 deaths per annum globally (Russo 
and Johnson, 2003). Despite intensified prevention efforts, E. coli remains a persistent pathogen in the 
US and around the world (Nyachuba, 2010). Traditionally, E. coli infections have been successfully 
treated using antimicrobial therapy; however, E. coli strains that are resistant to classical (Johnson et al 
2005), and modern (Kern 2011) antibiotics are on the rise. Anti-virulence therapy represents a promising 
new approach to fighting infection, as it removes heavy selective pressures to adapt from the pathogen. 
Virulence factors that target the coagulation system are extremely important during infection.  The most 
striking evidence of the importance of virulence factors directed at the coagulation system comes from 
Yersinia pestis. The loss of the plasminogen activating protease, Pla results in a million-fold increase in 
the median lethal dose of bacteria in mice (Sodeinde et al 1992). The importance of E. coli virulence 
factors targeted at the coagulation system requires further investigation. 
Immunoblotting of 6 clinical E. coli isolates, E. coli O86a: K61, and E. coli JM109 concentrated 
culture supernatants demonstrates the prevalence of proteases capable of cleaving and inactivating FV 
amongst pathogenic and non-pathogenic E. coli strains. Approximately 1/3 of the clinical isolates 
secreted proteases that were retained by a 100kDa filter, and were capable of cleaving and inactivating 
FV in NHP. These results show that some, but not all pathogenic E. coli strains produce large proteases 
capable of cleaving FV. Others have shown that E. coli secretes large proteases capable of cleaving FV 
(Brunder et al 1997); however, no effect on FV activity was measured. Further study is required to 
elucidate whether smaller secreted proteases are present in the culture supernatants of clinical isolates 
which did not proteolytically degrade and inactivate FV. E coli O86a: K61, the strain used by Samis et al 
2009 to study sepsis in a baboon model and the strain used in this study, secreted a protease which was 
capable of cleaving FV to a 250kDa partially/inactive product. The molecular weight (250kDa) of the 
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proteolytic cleavage product of FV in the baboon plasma was consistent with the cleavage product 
produced by the E. coli protease studied here, indicating the E. coli protease was likely responsible for 
FV cleavage and inactivation during experimental sepsis. Direct inactivation of purified FV (Data not 
shown) by the E. coli O86a:K61 secreted protease suggests that host proteases such as plasmin(ogen), 
which has been shown to be activated by E. coli proteases (Lundrigan and Webb, 1992),  and also 
generates a similar sized FV cleavage product (Samis, unpublished results) are not responsible for the 
inactivation event.  Although plasmin is a candidate host protease which is capable of cleaving and 
inactivating FVa, it has been demonstrated that plasmin activates the procofactor FV molecule after 30 
minute incubations in comparable activity assays (Lee and Mann 1989), which is inconsistent with 
results obtained in this study. The non-pathogenic laboratory E. coli strain JM109 also generated a FV 
cleavage product of 250kDa. Others have demonstrated that minor modifications to non-virulent 
housekeeping proteases may result in the generation of potent virulence factors (Kukkonen et al 2001). 
Further study is necessary to determine the virulent nature of the secreted E. coli JM109 protease. 
Nevertheless, the JM109 strain may be ideal as a model for studying proteolytic inactivation of FV 
because the strain is not pathogenic to humans.   
FV cleavage by the secreted E. coli O86a: K61 protease was also associated with decreased FV 
coagulation activity in the FV 1-stage microplate assay. Complete cleavage of the intact 330kDa human 
FV molecule to a 250kDa product was associated with an 80% decrease in FV 1-stage activity. These 
results are consistent with the results obtained by Samis et al 2009 in non-lethal and lethal experimental 
sepsis in baboons, where complete cleavage of FV to a 250kDa product was associated with an 80% 
decrease in activity.  The results suggest the 250kDa FV cleavage product generated by the secreted E. 
coli protease retains approximately 20% of the functional activity of the intact 330kDa procofactor.  
However, it is unclear whether the 250kDa product is still active, or if the 330kDa intact species is 
present at a concentration which is below the detection limit of the assay. Isolation of the 250kDa 
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cleavage product would be required to clarify the functional FV activity of this proteolytic product in a 
system of purified components.  
The inactivation of FV coagulation activity by the E. coli O86a: K61 protease also resulted in an 
increase in the extent of clotting. As discussed earlier, it is unclear whether this was the result of FV 
inactivation. It is possible that inactivation of a host protease by TFPI, which is responsible for “shutting 
down” coagulation, would generate this effect. TFPI, which would be expected to be present in NHP 
during tissue factor induced coagulation in the FV 1-stage activity assay, may also be inactivated by the 
E. coli protease.  Other E. coli proteases have been shown to inactivate TFPI (Yun et al 2009); however, 
further study is necessary to confirm whether TFPI is a target of the E. coli protease in this study.  
Curiously, when the E. coli protease was incubated with NHP and coagulation was induced via the 
Contact pathway (aPTT assay), there was a decrease in the extent of clotting compared to controls (Data 
not shown).  All other regulators of coagulation would be expected to effect the clotting event 
regardless of which pathway was used to induce clotting.   
The results indicate that the rate of clot formation remained unchanged in samples that were 
treated with the E. coli protease compared to samples treated with buffer. As indicated earlier, FV levels 
influenced the rate of clot formation. It is possible that the 250kDa cleavage product may still participate 
in the clot formation event in some way, and therefore has no effect on the rate of clot formation. 
Nevertheless, this result remains unclear. It is, however, clear that the E. coli protease increased the 
time for clot formation, and the resulting clot produced had an increased extent of clot formation 
compared to samples treated with buffer alone. 
The results indicate that when NHP is incubated with the E. coli protease, there was a 
prolongation in the aPTT time compared to samples treated with buffer. FV inactivation would be 
expected to prolong the time for clot formation in both TF-induced (FV 1-stage/E. coli protease activity 
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assay) and Contact pathway-induced (aPPT), as individuals deficient in FV present with prolonged PT and 
aPPT clot times (Huang and Keorper 2008). Unlike the FV 1-stage assay, the aPPT assay does not 
distinguish between which coagulation factors in the Contact/Common pathway have been inactivated, 
and it is therefore unclear whether other coagulation factors besides FV are inactivated by the E. coli 
protease. Altering the deficient plasma and the reagent used to initiate clotting in the FV 1-stage assay 
would allow for detection of protease-dependent inactivation events of other coagulation factors in 
future studies.  
The results indicate that when whole human blood was incubated with the E. coli protease, 
there was a prolongation in the time for TF-induced clot formation compared to samples treated with 
buffer. Automated whole blood coagulation assays have been used to evaluate coagulopathy (Larsen et 
al 2011), and are commonly used for monitoring coagulation during surgery (Bowers and Ferguson, 
1993). A modified version of the whole blood assay used in this study was able to detect activation of FV 
and/or FVIII (Kenichi et al 2010); however, the ability of the assay to detect factor V deficiency or 
inactivation has not been reported. Nevertheless, the prolongation in the time for clot formation when 
cellular components are present is consistent with bacterial secretions being responsible for the 
hemorrhagic diarrhea observed in the child that the E. coli strain was isolated from. Therefore, this 
result would be expected after proteolytic inactivation of FV by the E. coli protease. Further 
investigation is required to analyze inactivation of other coagulation factors that may contribute to the 
prolongation of clot time in the whole blood clotting assay. 
The results indicate that the E. coli protease was inhibited modestly by PMSF (Approximately 
20%) and almost completely (Approximately 90%) by A1PI. PMSF irreversibly inhibits serine proteases 
such as trypsin and thrombin by sulfonating the hydroxyl group of the serine residue at the active site 
(Gold 1967). PMSF is also capable of inhibiting some cysteine proteases (Scopes 1994). PMSF is an ideal 
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serine protease inhibitor for this study because of its relatively short half-life when dissolved in water. 
PMSF has a half-life of approximately 35 minutes in aqueous solutions of neutral pH at room 
temperature and is almost completely inactivated after 1 hour at room temperature (James 1977). 
These characteristics of irreversible inhibition and short half-life allow for experimental conditions 
where inhibition of the E. coli protease may be monitored without inhibiting the serine proteases of the 
coagulation cascade. The E. coli protease activity was reduced by approximately 20% after incubation 
with 1.5x the maximum suggested concentration of PMSF by the manufacturer (Sigma, Oakville, ON). 
This suggests, but does not prove that the E. coli protease is a serine protease.  Other non-serine 
proteases of E. coli have been inhibited by serine protease inhibitors (Mangel et al 1994). The E. coli 
protease was not inhibited by E64 or iodoacetamide which suggests that the protease is not a cysteine 
protease. The E. coli protease was also resistant to the antimicrobial tetracycline, which is a mild metal 
ion chelator which has been shown by others to inhibit metallo-proteases (Imamura et al 2001). 
Tetracycline was used to limit any effects on the coagulation proteases which also depend on metal ions 
(Ca2+) for functional activity. Tri-sodium citrate and EDTA are more commonly used to demonstrate that 
a protease is metal ion dependant; however, they were used to prevent coagulation during the blood 
drawing process and for the generation of FV-deficient plasma, respectively, and would therefore not be 
ideal for use in this study. The concentration of tetracycline incubated with the E. coli protease was 
comparable to the concentrations used by Imamura et al 2001, which suggests the E. coli protease is not 
metal ion-dependant. However, given the metal-ion dependant nature of FV and the coagulation 
cascade, an alternative substrate may be required to conclusively demonstrate the E. coli protease is not 
metal ion dependant.  
A1PI, commonly referred to as alpha 1-antitrypsin, is a plasma derived polypeptide which 
inhibits a broad range of human proteases, though human neutrophil elastase is considered its primary 
target (Kalsheker, 1988). A1PI inhibited the E. coli protease activity against FV by 90% at physiological 
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concentrations (1.5mg/ml) (Normal range: 1.5-3.1mg/ml (Deam et al 1989)). The plasma used during 
standard assaying of the E. coli protease activity was diluted 5-fold before it was incubated with an 
equal volume of the E. coli protease, and would therefore be expected to contain approximately 0.15-
0.31mg/ml A1PI, which may reduce the protease activity during Western blotting and the E. coli activity 
versus FV in human plasma assay.  A1PI deficiency is one of the most common inherited disorders in 
Caucasians (Kalsheker, 1988). Individuals who are deficient in A1PI are at an increased risk of lung 
infection by opportunistic pathogens (Chan et al 2007). A1PI levels increased in response to E. coli O86a: 
K61 during experimental sepsis in baboons, but was inactivated during the later stages of infection 
(Samis et al 2009). A1PI has been shown to be inactivated by bacterial enzymes (Padrines and Bieth 
1989) and bacterial toxins which produce anti-coagulant effects (Nlclasen et al 2011).  The potent 
inactivation of the E. coli protease by A1PI may support further study into its potential use as a 
therapeutic agent during E. coli infections. 
The results indicated that the E. coli protease activity versus FV was inhibited by Zn(II) and Cu(II), 
but not Fe (II). Others have reported that OmpT, a membrane bound E. coli aspartyl protease which 
activates plasminogen, is inhibited by divalent cations (Sugimura and Nishihara 1988). Zn2+ has been 
shown to inhibit aspartyl proteases by binding directly to the active aspartyl residue (York et al 1993), 
which suggests the E. coli protease may be an aspartyl protease. Cu2+ inhibited the E. coli protease 
versus FV, which is interesting because Cu2+ has also been shown to reduce A1PI inhibition towards 
trypsin and human neutrophil elastase (Kwon et al 1990), and A1PI was shown here to inhibit the E. coli 
protease. Fe2+ did not inhibit the E. coli protease activity versus FV at the concentrations tested. Others 
have demonstrated that proteases of E. coli which are capable of cleaving FV are also involved in iron 
acquisition during pathogenesis (Boisen 2009), which may be the case for the E. coli protease analyzed 
in this study.  
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The E. coli protease showed remarkable thermal stability, retaining over 50% of its activity after 
3 hour incubations at 95°C. The thermal stability of the E. coli protease may be a result of its association 
with OMVs, which have been shown to stabilize their protein cargo (Kulp and Kuehn 2010). Secreted 
bacterial proteins must be resistant to stresses because they are exposed to harsh environments; 
however, the thermal stability of this protease is unusual. Other E. coli proteases have been shown to be 
incredibly heat stable, such as the plasminogen activator OmpT, which is routinely boiled to allow for re-
folding during purification (Manel et al 1994). The thermal stability of the protease may be related to its 
ability to survive elevated temperatures in the host during infection, as other E. coli virulence factors 
have been reported to be heat stable (Lortie et al 1991).  
The results of this study indicate that E. coli O86a: K61 secretes OMVs. Although others have 
theorized that nearly all gram-negative bacteria secrete OMVs during their lifecycles (Ellis and Kuehn 
2010), the ability of EPEC strains to produce OMVs has not been reported. However, 
enterohaemorrhagic (EHEC) (Wai et al 2003), enterotoxigenic (ETEC) (Horstman and Kuehn, 2000), Shiga 
toxin producing (STEC) (Yokoyama et al 2000), uropathogenic (UPEC) (Kouokam et al 2006), and 
extraintestinal (ExPEC) (Scorza et al 2008) pathogenic E. coli strains have been shown to produce OMVs. 
OMV interactions with the coagulation system have not been reported. Transmission electron 
micrographs clearly demonstrate that E. coli O86a: K61 secretes OMVs which are heterogeneous in 
nature. Identification of the proteins which associate with these OMVs is of critical importance in order 
to understand their role(s) in deregulating the coagulation system through inactivation FV, as well as 
their role(s) in bacterial pathogenesis as a whole.  
Purification and isolation attempts of the E. coli protease from the OMVs has proved 
challenging, as the secreted protease did not fractionate from lipid using commonly used protocols such 
as ammonium sulphate precipitation, polyethylene glycol precipitation, Q-Sepharose anion exchange 
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chromatography (Over broad pH ranges), SP-Sephadex cation exchange chromatography (Over broad pH 
range), Benzamidine Sepharose serine protease affinity chromatography, or sucrose gradient 
ultracentrifugation. Although the E. coli protease was not purified to complete homogeneity, 
approximately 1000-fold purification was achieved from the initial culture supernatant using TFF 
filtration, ultracentrifugation, and Sephadex G-100 gel filtration chromatography. The inability to 
achieve protein fractionation and purification of the E. coli protease using precipitation techniques was 
likely due to the presence of OMVs, which have been reported to interfere with standard precipitation 
protocols (Kulp and Kuehn 2010). OMVs would also be expected to interfere with affinity based 
chromatography (Including ion exchange) by sterically restricting access of the protein to the functional 
groups on the column beads. Also, the size of the OMV may have prevented diffusion into the beads 
containing the functional groups. However, the purification methods in this study are comparable to 
methods used by others to isolate OMVs (Kulp and Kuehn 2010). The E. coli protease activity eluted with 
two proteins with molecular weights of 37kDa and 90kDa early on during Sephadex G-100 gel filtration 
chromatography, suggesting its association with the larger OMVs observed. It remains unclear whether 
these two proteins are related or different, as the 37kDa band may be a proteolytic breakdown product 
of the 90kDa species, and several E. coli proteases have been shown to auto-proteolytically degrade 
during secretion and purification, including several SPATEs which have been shown to cleave FV (Dutta 
et al 2002).  The non-symmetrical nature of the eluting protease activity from Sephadex G-100 gel 
filtration chromatography may be the result of a 3rd (110kDa) species. The large apparent molecular 
weight of two of the secreted proteins would be consistent with other reported SPATEs, and it is not 
unusual to have multiple SPATEs in one pathogenic E. coli strain (Dautin 2010).   
The anti-coagulant nature of the OMVs is somewhat surprising given that they are rich in LPS, 
which is a known pro-coagulant (Pernerstorfer et al 1999). The fact that the OMV associated protease 
targets FV for cleavage and inactivation is not surprising, as individuals who are FV deficient most often 
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present with bleeding episodes in skin, mucosa, and gastrointestinal tract (Huang and Koerper 2008). 
Although EPEC strains such as O86a: K61 do not typically enter the bloodstream, the OMVs may be 
secreted into the bloodstream after the development of an EPEC associated lesion within the gut. The 
anticoagulant nature of the OMVs would allow for entry through the developing fibrin clot at the site of 
infection. Once access to the bloodstream is obtained it is critical for the host to prevent the 
dissemination of the OMVs, as they are extremely virulent in nature and may cause mortality at very low 
concentrations in mice (Park et al 2010). EPEC strains may benefit from the generation of a net bleeding 
tendency in the host, as this would provide access to the bloodstream and iron.  EPEC strains have been 
reported with virulence factors which are capable of lysing red blood cells for the acquisition of iron 
(Larzabal et al 2010), a critical micronutrient required during their pathogenesis in hosts (Skaar 2010; 
Wooldridge and Williams 1993). Further study is required to determine whether the OMVs produced by 
E. coli O86a: K61 enter the bloodstream or whether they localize at the site of the EPEC lesion to 
promote bleeding. 
Further attempts to purify the secreted E. coli protease from OMVs have proven to be difficult. 
Disruption of the OMVs by detergents and solubilising reagents leads to immediate loss of protease 
activity. However, some solubilising reagents such as urea (1M) and β-mercaptoethanol (0.1%) 
increased protease activity towards FV by 2 fold, and up to 500 fold, respectively. The 37kDa species was 
purified to apparent homogeneity after solubilisation with 30mM CHAPS and Q-Sepharose anion 
exchange chromatography; however, attempts to reconstitute the protease activity towards FV were 
unsuccessful. Curiously, a protein of the same apparent molecular weight eluted later in the NaCl 
gradient with what appeared to be rough LPS by silver staining. These fractions possessed protease 
activity against FV in NHP.  
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Several characteristics of the E. coli protease from this study are consistent with it being OmpT, 
a 35kDa membrane bound aspartyl protease of E. coli which requires rough LPS for proteolytic function 
(Hwang et al 2007). OmpT is mildly inhibited by serine protease inhibitors, and may survive 
temperatures up to 95°C (Mangel et al 1994). OmpT is also inhibited by Zn2+ and Cu2+ (Sugimura and 
Nishihara 1988). OmpT retains proteolytic activity at up to 4M urea, and prefers denatured substrates 
(White et al 1995). OmpT is also expressed by E. coli K-12 strains (Hritonenko and Stathopoulos 2007), 
and would therefore be present in E. coli JM109. It is possible that OmpT or a related protease is being 
secreted into culture media via the OMVs; however, this has not been reported by others.  
N-terminal sequencing of the 3 main proteins from E. coli OMVs was perfomed to identify the 
protease. N-terminal sequencing of the 37kDa protein did not confirm the presence of OmpT. Instead, 
several porins and two SPATEs displayed significant amino acid homology to the N-terminal sequence 
obtained. YedS , OmpC, OmpN, YddL, and OmpF are porins of E. coli with approximate molecular 
weights which are within 5kDa of the predicted 37kDa molecular weight shown by SDS-PAGE, and 
showed 100% positive matches to the basic local alignment search tool  (BLAST) sequence. Porins have 
been reported to associate with OMVs of other gastro-pathogens (Mullaney et al 2009); however, 
proteolytic activity has not been reported with these proteins. Pic, an E. coli SPATE which has been 
demonstrated to cleave FV, has two distinct regions with homology (100% and 67%) to the sequence 
obtained by N-terminal sequencing, at residues 86-91 and 854-859, respectively. Pic is translated as a 
146kDa polypeptide, which undergoes proteolytic processing during secretion. The active secreted form 
is 109.4kDa (Henderson et al 1999). N-terminal sequencing data obtained in this study was inconsistent 
with others who demonstrated N-terminal sequencing, starting at G56 and N1096 for the secreted and 
membrane bound component, respectively (Henderson et al 1999). However, it is possible that the 
intact Pic protease was proteolytically degraded, and N-terminal sequencing data was obtained from a 
cleavage product. Pic’s role as a virulence factor remains somewhat unclear, but it is capable of cleaving 
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FV and haemoglobin (Boisen et al 2009). Pic also provides serum resistance, allowing bacterial growth in 
serum of non-pathogenic bacteria which would otherwise be killed. Others have speculated that this is a 
result of inactivation of a complement factor (Henderson et al 1999), but complement factor 
inactivation has not been confirmed (Dautin 2010). Hbp, another E. coli SPATE, also showed homology 
(83%) to the N-terminal sequence obtained at residues 83-88, though again at a sight which would not 
be expected to be N-terminally exposed unless proteolytic degradation took place. Hbp, like Pic, 
proteolytically degrades haemoglobin; however, Hbp is also capable of binding heme, and therefore has 
been linked to iron acquisition (Otto et al 2002). Proteolytic processing of FV has not been reported with 
Hbp. Further sequence analysis of the 3 semi-purified E. coli proteins is required to conclusively 
determine their identity.  
This study has demonstrated that a secreted E. coli O86a: K61 OMV associated protease 
behaves as a virulence factor that targets the coagulation system through inactivation of FV, to promote 
a bleeding tendency in infected hosts. The OMV associated E. coli protease, when treated with whole 
blood or blood plasma, significantly prolonged the time required for contact or tissue factor activated 
fibrin production. The E. coli OMV protease would be expected to be concentrated at or near the site of 
infection where significant FV inactivation would occur. Inactivation of FV would result in a fitness 
advantage by increasing the likelihood of bacterial survival and transmittance to new host through 
deregulation of the host immune response. Further study is required to determine whether the secreted 
E. coli OMV protease gains access to the bloodstream to promote further deregulation of the host’s 
systems, or whether localization occurs at the site of the EPEC associated lesion to promote bleeding for 
the acquisition of nutrients. 
In future research, a combination of tandem mass spectrometry protein sequencing, N-terminal 
protein sequencing, and PCR gene sequencing could be implemented to conclusively determine the 
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identities of all three proteins which associate with the OMVs. Detergent solubilisation and column 
chromatography could be implemented to purify the secreted E. coli OMV protease to homogeneity so 
that it may be further characterized biochemically. This may require the use of molecular genetic 
techniques to allow for overexpression of the E. coli protease. The effects of the purified E. coli OMV 
protease on other coagulation factors could also be examined.  The effects of the purified protease on 
fibrin formation in human plasma and its effects of fibrin degradation in human plasma could also be 
explored. Using protease deletion constructs, the effects of the secreted E. coli OMV protease on 
bacterial growth in vitro and virulence towards animal cells/models in vitro/ in vivo may also be 
examined. Finally, the secreted E. coli OMV protease may represent a target for new diagnostics, 
therapeutics, anti-virulent drug design, and/or vaccines. Clearly, future research of the effects of the 
secreted E. coli OMV protease on the coagulation, immune, and complement systems is warranted to 
firmly establish its role as a virulence factor that enhances bacterial proliferation and transmission by 
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